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SUMMARY 
In recent years, substantial progress in gene therapy has been made as proofed by 
several successful clinical trials providing substantial benefit to patients and the first 
marketing authorization of an adeno-associated virus (AAV) vector-based medical 
product. Especially lentiviral and AAV vectors represent promising tools for gene 
transfer. They have been further improved to ensure safety and efficiency. One 
strategy to customize these viral vectors is the generation of receptor-targeted 
vectors that restrict gene delivery to cells expressing the targeted receptor. The first 
part of this thesis compares lentiviral and AAV vectors targeted to the receptor 
Her2/neu which is overexpressed in various tumor cells. This is for the first time a 
true side by side comparison of this totally different vector types, since here, both use 
the same receptor for cell entry. The second part investigates the potential of 
receptor-targeted lentiviral gene transfer into human hematopoietic stem cells (HSCs) 
via the cell surface protein CD105 and evaluates if CD105 is a marker for human 
long-term repopulating HSCs. 
The Her2-targeted lentiviral and AAV vector had been generated and characterized 
before (Münch et al., 2011; Münch et al., 2013). Both particles display a Her2/neu 
specific targeting ligand, the designed ankyrin repeat protein 9.29. First, functional, 
genomic and physical titers of Her2-LV and Her2-AAV vector stocks were determined 
side by side to allow precise normalization of both vector types. While the Her2-LV 
vector stocks showed higher genomic titers, Her2-AAV vectors comprised more 
functional particles per genome containing particles. Accordingly, about 10-fold more 
genome copies of Her2-LV than Her2-AAV had to be administered systemically in a 
subcutaneous tumor mouse model for detectable transgene expression. Analysis of 
the vector distribution short time after systemic administration in vivo revealed that 
the non-enveloped Her2-AAV vector circulated stably in the blood of mice for a 
prolonged time compared to Her2-LV. Accumulation of Her2-AAV within the target 
tissue occurred only after 24 hours.  
Lentiviral vectors are currently the preferred vector type for the modification of HSCs 
due to their capability of integrating the transgene into the host cell’s genome. 
Thereby the entire hematopoietic system can be reconstituted with cells carrying the 
corrected gene. True HSCs which are capable of self-renewal and differentiate into 
  SUMMARY 
2 
 
all hematopoietic lineages can be identified by the expression of specific cell surface 
markers. In mice, CD105 was previously shown to be present on most immature, 
long-term repopulating HSCs. After confirming that human CD105 is expressed on 
30-80% of human CD34+ cells, CD34+ cells were transduced with a lentiviral vector 
targeted to human CD105 (CD105-LV) and transplanted into NOD-scid IL2Rγ-/- mice. 
Stable reporter gene expression in engrafted cells was detected long-term in all 
human hematopoietic lineages in bone marrow, spleen and blood. In addition, 
competitive repopulation experiments in mice showed a superior engraftment of 
CD105-LV transduced CD34+ cells in bone marrow and spleen compared to cells 
transduced with a conventional non-targeted lentiviral vector confirming CD105 as a 
marker for early HSCs with high repopulating capacity.  
The data shown in this thesis highlight the potential of receptor-targeted vectors to 
trace cell subsets and identify new markers for specific cell populations. In addition, it 
demonstrates the potential of comparing vectors derived from different virus families 
once they have been targeted to the same entry receptor.   
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ZUSAMMENFASSUNG 
Während der letzten Jahre wurden bedeutende Fortschritte im Bereich der 
Gentherapie erzielt, was durch mehrere erfolgreich durchgeführte klinische Studien, 
die zu therapeutischen Verbesserung für die Patienten führten, sowie durch die erste 
Markteinführung eines Adeno-assoziierter Virus (AAV) Vektor basierten 
Therapeutikums bestätigt wurde.  Vor allem lentivirale und AAV Vektoren stellen 
vielversprechende Hilfsmittel für den Gentransfer dar. Sie wurden stetig 
weiterentwickelt, um deren Sicherheit und Effizienz zu gewährleisten. Eine Strategie, 
die viralen Vektoren anzupassen, ist das sogenannte Rezeptortargeting, das den 
Gentransfer nur in Zellen, die einen definierten Rezeptor exprimieren, ermöglicht. Der 
erste Teil dieser Dissertation vergleicht lentivirale und AAV Targetingvektoren, die an 
den Zielrezeptor Her2/neu, ein Oberflächenprotein, das in vielen Tumorzelltypen 
überexprimiert ist,  binden. Dieser direkte Vergleich zeigt Einblicke in Leistung, 
Verteilung und Anwendbarkeit von zielgerichteten lentiviralen und AAV Vektoren. Der 
zweite Teil dieser Arbeit untersucht das Potential eines zielgerichteten lentiviralen 
Vektors Gene in hämatopoetische Stammzellen (HSZ) einzuschleusen. Der 
Gentransfer erfolgt nach Bindung an das Oberflächenprotein CD105 und untersucht 
dabei gleichzeitig, ob CD105 ein Oberflächenmarker für humane lang-zeit 
repopulierende HSZ ist. 
Lentivirale und AAV Vektoren, die über die Bindung an den Rezeptor Her2/neu 
Gentransfer vermitteln, waren vor Beginn dieser Arbeit generiert und charakterisiert 
worden (Münch et al., 2011; Münch et al., 2013). Durch die Präsentation des 
gleichen Targetingliganden auf der Vektoroberfläche binden beide Vektortypen an 
den gleichen Zielrezeptor, was einen direkten Vergleich beider Vektortypen in vitro 
und in vivo ermöglicht. Zunächst wurden funktionale, genomische und physische 
Titer von Her2-LV und Her2-AAV Vektorstocks nebeneinander bestimmt, sodass eine 
genaue Normalisierung beider Vektortypen ermöglicht wurde. Die Her2-LV 
Vektorstocks beinhalteten mehr Genomkopien, allerdings enthielten Her2-AAV 
Vektorstocks mehr funktionale Partikel pro Genomkopien. Daher waren etwa 10-fach 
mehr Genomkopien des Her2-LV als des Her2-AAV in einem subkutanen 
Tumormausmodell nötig, um eine effiziente Genexpression zu erreichen. Die Analyse 
der Vektorverteilung kurze Zeit nach intravenöser Vektorinjektion zeigte, dass der 
nicht behüllte Her2-AAV länger im Blut zirkuliert als Her2-LV. Während der ersten 24 
  ZUSAMMENFASSUNG 
4 
 
Stunden nach Vektorgabe konnte keine Akkumulation von Her2-AAV Partikeln im 
Zielgewebe beobachtet werden.  
Wegen ihrer Fähigkeit, das Transgen in das Genom der Zielzelle zu integrieren, sind 
lentivirale Vektoren der präferierte Vektortyp für die Modifikation von HSZ. So kann 
das gesamte hämatopoetische System mit Zellen rekonstituiert werden, die das 
korrigierte Gen tragen. Echte HSZ besitzen die Fähigkeit sich selbst zu erneuern und 
sind gleichzeitig in der Lage, in alle hämatopoetischen Zellen auszudifferenzieren. 
Diese Stammzellen können anhand von bestimmten Oberflächenproteinen 
identifiziert werden. In Mäusen konnte CD105 als ein Rezeptor bestimmt werden, der 
auf unreifen, lang-zeit repopulierenden HSZ zu finden ist. In dieser Arbeit wurde 
bestätigt, dass humanes CD105 auf 30-80% der humanen CD34+ Zellen exprimiert 
wird. Anschließend wurden CD34+ Zellen mit einem lentiviralen Vektor transduziert, 
der an den humanen CD105 Rezeptor (CD105-LV) der Zielzellen bindet, und in 
NOD-scid IL2R-/- Mäuse transplantiert. In allen humanen hämatopoetischen Linien 
im Knochenmark, Milz und Blut wurde eine langfristig stabile Expression des 
Reportergens nachgewiesen. In einem Kompetitionsexperiment konnte außerdem 
gezeigt werden, dass CD34+ Zellen, die mit CD105-LV transduziert wurden, in 
Knochenmark und Milz einen höheren Transplantationserfolg zeigten als Zellen, die 
mit einem konventionellen nicht ziel-gerichteten lentiviralen Vektor transduziert 
wurden. Dies bestätigt CD105 als Marker für primitive HSZ, die eine hohe 
Repopulationseigenschaft besitzen.  
Die Daten, die in dieser Arbeit gezeigt werden, verdeutlichen das Potential von 
Vektoren, mittels Rezeptortargeting Zellsubpopulationen zu markieren und zu 
verfolgen, was eine Identifikation von neuen Markern auf spezifischen 
Zellpopulationen ermöglicht. Des Weiteren demonstriert diese Arbeit die Möglichkeit, 
verschiedene virale Vektortypen, die den gleichen Zelleintrittsrezeptor verwenden, zu 
vergleichen.  
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1. INTRODUCTION 
1.1 Gene therapy 
Gene therapy is expected to cure or prevent human diseases by delivery of a 
functional, therapeutic gene or by transfer of genes leading to the reduction or 
elimination of harmful gene products or cells. First clinical gene therapy studies were 
already conducted 25 years ago. Since then, the therapeutic approaches have been 
improved continuously. As vehicles for the delivery of transgenes, integrating and 
non-integrating viral and non-viral vectors have been used. The focus of the first 
gene therapy studies was on the treatment of primary immune deficiencies since in 
absence of a suitable bone marrow donor for these, gene therapy represents the only 
therapeutic option.  
 
1.2. Milestones of viral vector-based gene therapy 
Primary immune deficiencies (PID) are currently treated either by allogenic 
hematopoietic stem cell transplantation (HSCT) or by ex vivo gene modification. For 
HSCT, hematopoietic stem cells (HSCs) from a matching donor are infused into the 
patient early after detection of the disease. However, matching donors are not 
available for each patient. Therefore, genetic modification of autologous HSCs 
represents an alternative strategy. CD34+ cells from bone morrow (BM) or cells from 
granulocyte colony stimulating factor (GM-CSF) mobilized peripheral blood are 
harvested from the patients. Then, the cells are manipulated ex vivo and reinfused 
into the patients. The first clinical trial for PID gene therapy was conducted in 1990 
treating two children suffering from adenosine deaminase (ADA) deficiency by 
autologous transplantation of ex vivo corrected T-lymphocytes using a 
gammaretroviral vector. Despite normalization of T-lymphocyte counts in the blood 
and improvement of ADA enzyme activity in one of the patients, both patients had to 
remain on enzyme replacement therapy (Blaese et al., 1995). In the approach to treat 
SCID-X1 patients by gammaretroviral vector mediated gene therapy, the T-cell 
immune functions were fully restored in 18 out of 20 patients. However, 5 of the 
patients developed acute T-cell lymphoblastic leukemia (T-ALL) 2-5.5 years after 
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therapy caused by insertional activation of the proto-oncogene LMO2 (LIM domain 
only 2) (Hacein-Bey-Abina et al., 2003; Howe et al., 2008). 
Due to the occurrence of additional cases of leukemia in other clinical trials treating 
patients with Wiskott-Aldrich syndrome (WAS) (Persons and Baum, 2011; Braun et 
al., 2014), the integration profile of retroviral vectors was investigated intensively. It 
was found that gammaretroviral vectors tend to integrate into or near to gene 
regulatory regions such as enhancer, promoter genes or locus control regions. By 
comparing the integration sites of the affected patients, integration hot spots 
(especially LMO2, MDS-EVI1) were identified (Hacein-Bey-Abina et al., 2003; Ott et 
al., 2006). Vector integration into these genes led to clonal dominance associated 
with leukemia. In contrast to gammaretroviral vectors (Wu et al., 2003; Palma et al., 
2005; Deichmann et al., 2007), lentiviral vectors (LVs) preferable integrate into active 
transcriptions units and are able to transduce non-dividing cells; (Schröder et al., 
2002; Mitchell et al., 2004; Wang et al., 2009).  
By the generation of self-inactivating lentiviral vectors (SIN-LV) (see chapter 1.3) the 
safety of these vectors was significantly improved. Therefore, SIN-LVs are the 
preferred tool for the manipulation of HSCs today. So far, several phase I/II clinical 
trials using SIN-LVs are ongoing including the treatment of WAS (Aiuti et al., 2013), 
ADA-SCID (NCT01380990), chronic granulomatous disease (CGD) (NCT02234934), 
X-linked adrenoleukodystrophy (X-ALD) (Cartier et al., 2009; Cartier et al., 2012), 
metachromatic leukodystrophy (MLD) (Biffi et al., 2013) and -thalassemia 
(Cavazzana-Calvo et al., 2010). So far, 10 patients has been enrolled in the current 
WAS trial. Autologous HSCs were modified with a VSVG-pseudotyped SIN-LV ex 
vivo. The expression of WAS protein was restored, resulting in increased platelet 
counts, enhanced immune functions and improvement of clinical disease symptoms 
(Aiuti et al., 2013). Genetic modifications of HSCs to correct X-ALD (Cartier et al., 
2009) and MLD (Biffi et al., 2013) have been resulting in therapeutic effects in two 
other gene therapy trials. In addition to the clinical benefits, in all of these studies no 
clonal outgrowth has been observed so far with one clinical trial treating -
thalassemia being the exception. In this study which was initiated in 2007 the LV 
integrated into the tumor suppressor gene high mobility group AT-hook 2 (HMGA2) 
leading to benign clonal expansion of cells within the myeloid lineage (Cavazzana-
Clavo 2010).  
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Other promising tools for gene therapy are adeno-associated virus (AAV)-derived 
vectors. They are highly stable, producible in high titer vector stocks, show low 
immunogenicity and do not integrate into the host’s genome but are predominantly 
present episomally (Philpott et al., 2002). Therefore, AAV vectors are used for gene 
correction of post-mitotic tissues such as the retina, liver, central nervous system, 
and skeletal and cardiac muscle. In the first gene therapy trials treating patients with 
inherited eye disease, Leber’s congenital amaurosis (LCA), the retinal pigment 
epithelium-specific protein 65kDa (RPE65) was expressed after subretinal 
administration of a AAV2 vector leading to improvements in vision. In addition to the 
clinical benefit, the immune response against the vector itself or the transgene was 
very low and the therapy well tolerated (Bainbridge, James W B et al., 2008; 
Hauswirth et al., 2008; Maguire et al., 2008; Jacobson et al., 2012). Demonstrating 
proof-of-concept, these first three trials facilitated initiations of other clinical eye 
studies. Within the first clinical study to treat hemophilia B by AAV vector mediated 
gene therapy, therapeutic relevant levels of factor IX were not achieved but this trial 
demonstrated safety and possible application of intramuscular injection of AAV 
vectors for gene therapy (Kay et al., 2000). In subsequent clinical studies, the focus 
was on transduction of liver cells that are more prone to secrete factors to the 
circulating blood (Manno et al., 2006) and are thought to induce immune tolerance 
against transgenes following vector administration via the portal vein (Mays and 
Wilson, 2011). The expression of factor IX increased to therapeutic relevant levels, 
but also dropped in few patients several weeks after gene therapy. This fact was put 
down to memory T-cells that recognized AAV capsid proteins by some investigators 
(Mingozzi and High, 2011) and to induction of cytotoxic T-cell response against the 
transgene by others (Li et al., 2009). AAV vector mediated gene transfer has been 
shown a notable safety profile and efficacy record in vivo, leading to the granting of 
the first marketing authorization in the western world for an AAV-based therapeutic 
medicine in November 2012 by the European Commission. Previously, alipogen 
tiparvovec (also known as Glybera) was successfully tested in several clinical trials 
treating the ultra-rare familial lipoprotein lipase deficiency (LPLD). The naturally 
occurring gain of function mutated gene LPLS447X was administered intramuscular by 
a serotype 1 AAV vector that demonstrates high muscular tropism (Mingozzi et al., 
2009). Treated patients showed clinical improvement up to 2 years after 
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intramuscular vector administration (Gaudet et al., 2012) while sustained transgene 
expression was not impaired by immune response (Ferreira et al., 2014).  
 
1.3 Basics about lentiviral vectors  
Lentiviral vectors are derived from lentiviruses which belong to the Retroviridae 
family. Lentiviruses, such as the human immunodeficiency virus 1 (HIV-1), are 
enveloped viruses with a diploid, positive sense, single stranded RNA genome. The 
envelope consists of host cell membrane and viral envelope proteins (Env) and 
encloses the capsid which is composed of approximately 2000 p24 proteins (Wilk et 
al., 2001). Within the capsid, viral replication enzymes and the two linear RNA 
molecules surrounded by nucleocapsid proteins are located. The genome, which has 
a size of about 7 to 13 kb per monomer, encodes for the genes gag/pol and env. The 
gag gene provides all structural proteins such as matrix protein, capsid protein, 
nucleocapsid protein as well as SP1, SP2 and p6. The pol gene encodes for the 
reverse transcriptase, protease and integrase, env for the Env protein. The protein-
encoding regions are flanked at both ends by long terminal repeats (LTR) which 
consist of 3’ unique elements (U3), repeat elements (R) and 5’ unique elements (U5). 
The LTRs contain promoter and enhancer sequences, the transactivation response 
element (TAR), the poly-adenylation signals and the att repeats that are necessary 
for viral integration into the host genome. The packaging signal psi is responsible for 
the packaging of genomic RNA into the viral particles (Xie et al., 2002; Freed and 
Martin, 2006; Pluta and Kacprzak, 2009). 
Instead of the viral genome, lentiviral vectors contain a transgene. Therefore, LVs are 
replication deficient, but they can transfer and integrate a gene of interest into the 
genome of mammalian cells which is termed transduction. Most of the LVs are 
derived from HIV-1. Similar to lentiviruses which can not only infect mitotically active 
cells, LV can transduce non-dividing cells. This makes them a promising tool for gene 
therapy. However, several safety issues have to be considered using LVs. Long-term 
follow up studies of clinical trials revealed that the risk of abnormal clonal expansion 
of LVs transduced cells is rather low compared to gammaretroviral vector studies 
since LV tent to integrate not near promoters and regulatory elements, but into active 
transcription units (Mitchell et al., 2004). Another safety concern that needs to be 
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minimized is the potential of development of replication competent lentiviruses within 
vector preparations. Therefore, transfection protocols were established in which 
gag/pol and env genes are split onto two separate plasmids that both lack the 
packaging signal psi. In addition, accessory proteins that are not essential for the 
production of LVs, namely Vpr, Vif, Vpu, and Nef, are deleted from the packaging 
plasmid leaving tat and rev besides gag/pol (Zufferey et al., 1997). Only the transfer 
plasmid which encodes for the gene of interest contains a functional psi signal which 
is the reason that only the transgene is packaged into the generated vector particles.  
Further improvement of vector safety was achieved by generation of self-inactivating 
(SIN) vectors. Here, the U3 region of the 5′ LTR is replaced with a heterologous 
promoter, e.g. the cytomegalovirus (CMV) promoter, resulting in a Tat-independent 
transcription. In addition, the transcriptional unit is deleted from the LTRs by partially 
deletion of the U3 region of the 3′ LTR (Miyoshi et al., 1998). LVs have a large cargo 
capacity which is in general 7-9 kb, but can be exhausted up to 18 kb, although this 
reduces the functional titers of the vector stocks (Kumar et al., 2001). LVs are 
produced by transient or stable transfection of packaging cell lines, usually HEK293T 
cells, since they are highly susceptible to transfection and express the SV40 T-large 
antigen which allows replication of plasmids containing the SV40 origin of replication 
(Soneoka et al., 1995). The vector particles bud from the cell membrane of the 
producer cells and then can be harvested from the cell supernatant. As a result of the 
budding process the vector envelope consists of the cellular lipid bilayer as well as 
viral envelope proteins that are expressed on the cell surface.  
Therefore, the cell specificity of LV depends on the envelope protein used for 
transfection. By substitution of the natural Env protein with other viral surface 
proteins, the tropism of the LV can be altered – a procedure known as pseudotyping. 
The first reports about successful pseudotyping demonstrated incorporation of 
murine leukemia virus (MLV) or HTLV-1 Env into HIV-1-based LVs (Page et al., 
1990; Landau et al., 1991). Since then, lots of glycoproteins from different viruses 
were used for pseudotyping (Cronin et al., 2005; Frecha et al., 2008). Nevertheless, 
the most common pseudotype is the glycoprotein of the vesicular stomatitis virus 
(VSVG). Its broad tropism enables VSVG pseudotyped LVs (VSVG-LV) to transduce 
all mammalian cells while maintaining high titers and excellent stability of virions. 
However, VSVG-LVs are not applicable for in vivo gene therapy, since complement- 
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and antibody mediated immune response against the glycoprotein will occur (DePolo 
et al., 2000; Higashikawa and Chang, 2001). In addition, despite the successful 
application of VSVG-LV in several hematopoietic stem cell-based therapeutic 
approaches, unstimulated human HSCs lack the entry receptor LDL-R (low-density 
lipid receptor) for VSV (Amirache et al., 2014). Therefore, the transduction of HSCs 
requires usually several days of ex vivo pre-stimulation, followed by 1 – 3 rounds of 
transduction at a very high multiplicity of infection (MOI) for efficient gene transfer 
(Aiuti et al., 2013; Biffi et al., 2013). This can be circumvented by transduction of the 
cells using a receptor-targeted LV (see chapter 1.5.1).  
 
1.4 Basics about adeno-associated viral (AAV) vectors  
Adeno-associated viruses belong to the family of Paroviridae. One characteristic of 
AAV is that successful replication is dependent on a helper virus such as vaccinia 
virus (Schlehofer et al., 1986), herpes simplex virus (Buller et al., 1981), human 
cytomegalovirus (McPherson et al., 1985) or adenovirus (Casto et al., 1967), leading 
to the classification to the genus of Dependovirus. Replication of AAV is initiated by 
transactivation of the AAV promoters by proteins of the helper virus. In the absence 
of a helper virus, AAV undergoes latent infection by integrating into the chromosome 
19 of the host’s genome (Kotin et al., 1990; Samulski et al., 1991) or persisting 
episomally until the presence of a helper virus initiates the replication cycle of AAV. 
The icosahedral formed capsid consists of 60 subunits that are composed of the 
three structural proteins VP1, VP2 and VP3 (Xie et al., 2002). The single-standed 
DNA genome is flanked by two inverted terminal repeats (ITRs) forming hair-pin 
structures. The ITRs are involved in genome integration, packaging and regulation of 
gene expression. They also contain binding elements required for the initiation of 
replication. The three capsid proteins are translated from one mRNA by alternative 
splicing resulting in expression of different amounts of proteins (Berns and Parrish, 
2006). 
So far, several human and non-human primate AAV serotypes have been identified. 
Genome size and organization are identical among these serotypes, but the capsid 
protein homology and the target entry receptors differ leading to diverse tissue 
tropism (Wu et al., 2006). For AAV2, heparin sulfate proteoglycan (HSPG) has been 
  INTRODUCTION 
11 
 
found to be the primary binding receptor. HSPG is mainly expressed in liver tissue, 
resulting in a strong liver tropism (Kern et al., 2003; Opie et al., 2003).  For gene 
therapeutic approaches the gene of interest is integrated into the AAV genome. The 
size of the transgene is limited to approximately 4.4 kb.  
In addition to the single-stranded AAV (ssAAV) vectors, self-complementary AAV 
(scAAV) vectors were developed (McCarty et al., 2001). In one of the ITRs the 
terminal resolution site is removed resulting in primarily dimeric inverted repeat forms 
of the AAV genome (McCarty et al., 2003). Thereby, the host cell-mediated synthesis 
of a double-stranded DNA from the single stranded AAV vector DNA is circumvented 
and the synthesis of the transgene occurs faster and transduction efficiency is 
enhanced (McCarty et al., 2003; Wang et al., 2003). Although, compared to ssAAV, 
the cargo capacity of scAAV is limited to about half the size, less vector particles are 
required for comparable transduction efficiencies (McCarty, 2008).  
AAV vectors have been engineered to alter the natural tropism. On the one hand, this 
can be achieved by a rational design of the AAV capsid such as generation of mosaic 
(Hauck et al., 2003) or chimeric capsids (Hauck and Xiao, 2003). On the other hand, 
modifications of the capsid can be introduced in a library-based high throughput 
format. By error-prone PCR, DNA shuffling or insertion of random peptides with 
subsequent directed evolution, AAV vector mutants highly efficient for the cell type 
applied for selection were identified (Müller et al., 2003; Perabo et al., 2003; 
Maheshri et al., 2006; Perabo et al., 2006; Michelfelder et al., 2007; Grimm et al., 
2008). Indeed, the tropism of the AAV vectors is altered by these methods, but gene 
delivery is not restricted to specific cell types, but usually expanded. Therefore, a 
flexible receptor targeted gene transfer approach was established by Münch et al. 
that will be described in chapter 1.5.2 in detail (Münch et al., 2013). 
 
1.5 Receptor targeting 
For therapeutic applications gene transfer into all cells is not desirable but should be 
restricted to cells affected by the dysfunctional gene. The expression of the 
transgene in healthy cells is especially of concern, if a suicide gene for example 
encoding the herpes simplex virus thymidine kinase (HSV-TK) is delivered. 
Therefore, viral vectors have been generated that allow directed gene delivery.  
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1.5.1 Receptor-targeted lentiviral vectors  
The normal tropism of lentiviral vectors can be altered by pseudotyping of the vector 
particles. Here, the natural glycoprotein of HIV-1 is replaced with glycoproteins of 
another virus species (Cronin et al., 2005; Frecha et al., 2008). Thereby, the tropism 
can either be broadened as in the case for VSVG pseudotyped LV or restricted to the 
normal tropism of the expressed glycoprotein. Efficient incorporation of these 
glycoproteins into vector particles often requires modification of the cytoplasmatic tail 
such as truncations or construction of chimeric glycoproteins (Sandrin et al., 2002)  
The glycoproteins can be further engineered by mutation of the natural receptor 
recognition site or by presentation of a specific targeting ligand. 
The principal of receptor targeted lentiviral vectors used in this thesis was established 
by Funke et al. HIV-1 particles were pseudotyped with the measles virus 
hemagglutinin (H) and fusion (F) proteins. The cytoplasmatic tail of the H protein was 
truncated by 18 amino acids and that of the F protein by 30 amino acids to allow 
efficient incorporation into the vector particle. In addition, the natural binding site was 
mutated preventing transduction of cells expressing the measles virus recognition 
receptors CD46, SLAM and nectin-4. Originally, a single-chain antibody against the 
surface protein CD20 was fused to the ectodomain of the H protein restricting gene 
transfer to CD20+ cells (Funke et al., 2008). The flexibility of this targeting system 
was demonstrated by exchanging the single-chain antibody against CD20 with further 
single-chain antibodies, but also with designed ankyrin repeat proteins (DARPins). 
Thereby, LVs targeted to a broad variety of cell surface receptors and the 
corresponding cell types including CD105+, CD4+, CD8+, CD30+ or Her2/neu+ cells 
were obtained (Anliker et al., 2010; Münch et al., 2011; Zhou et al., 2012; Abel et al., 
2013; Friedel et al., 2015).  
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Figure 1: Receptor targeted LV. The cytoplasmatic domains of measles virus F and H proteins are 
truncated. The natural binding site within the H protein is mutated and blinded for the natural receptors 
of measles virus. In addition, a targeting ligand, here a single-chain antibody, is fused to the 
ectodomain of the H protein allowing transduction of receptor positive targeting cells only.  
 
 
1.5.2 Receptor targeted AAV vectors 
Incorporation of receptor ligands into the capsid of AAV vectors is not well-tolerated. 
Therefore, the identification of suitable ligands with respect to length and sequence 
are critical for proper capsid assembly. In addition, only the fusion of a targeting 
ligand to the N-terminus of the VP2 protein allows the production of functional vector 
particles (Yang et al., 1998; Wu et al., 2000). A universal targeting approach was 
investigated by Ried et al. They inserted a truncated immunoglobulin-binding domain 
into AAV2 particles that allows loading of the vector particle with various antibodies. 
These vectors transduced target cells specifically, but the titers remained very low 
(Ried et al., 2002). Therefore, retargeting of AAV2 vectors with small high binding 
affinity molecules, namely DARPins was established by Münch et al. A DARPin 
against Her2/neu was fused to the N-terminus of the AAV2 VP2 capsid protein 
resulting in successful incorporation of the receptor targeting domain into the vector 
particles. In addition, by mutation of the native binding site HSPG the generated AAV 
vector particles were blinded for the natural receptor leading to restricted gene 
transfer into Her2/neu+ cells. Furthermore, by de-targeting of the Her2-AAV vector 
from the natural liver tropism, severe liver damage was prevented compared to the 
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AAV2 wild-type vector after systemical administration in vivo. The therapeutic 
relevance of the newly generated targeting vector was demonstrated by delivery of 
the HSV-TK gene into Her2/neu positive tumor tissue after i.v. injection. In 
combination with injection of the prodrug ganciclovir, growth of the tumor was 
reduced resulting in prolonged survival of the mice (Münch et al., 2013). This 
retargeting approach was further optimized by separation of DARPin containing AAV 
particles from DARPin-deficient particles by immobilized metal ion affinity 
chromatography resulting in tissue specific transgene expression without detectable 
off-targeting effects in a mouse model. The flexibility of the system was shown by 
generation of two other receptor targeted vectors, namely CD4-AAV and EpCAM-
AAV (Münch et al., 2015). 
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Figure 2: Generation of receptor targeted AAV vectors. By transient transfection of producer cells 
AAV particles are generated. The VP2 start codon as well as the HSPG-binding site of the AAV2 
capsid gene were mutated resulting in expression of VP1 and VP2 proteins. The DARPin-VP2 capsid 
protein is expressed from a separate plasmid. The transfer vector contains ITRs, resulting in 
packaging of the transgene into the assembled particle.  
 
1.6 Cell surface markers 
Using receptor targeted viral vectors, transgenes can be delivered selectively into 
specific cell types in vitro as well as in vivo. Target cells can be defined by the 
expression of surface molecules and depending on the target cell population the 
receptor of choice can be selected. In tumor therapy, progression of tumor or 
response to treatment and risk of recurrence is often determined by monitoring of 
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established surface markers that are overexpressed in diverse tumor types. Among 
these markers is the human epidermal growth factor receptor 2 (Her2/neu) a type 1 
receptor tyrosine kinase belonging to the epidermal growth factor family. It is over-
expressed on varies cancer cells such as pancreatic, ovarian and breast cancer cells 
(Slamon et al., 1987; Slamon et al., 1989; Hall et al., 1990). Other common tumor 
markers include but are not limited to the epithelial cell adhesion molecule (EpCAM), 
the epidermal growth factor receptor (EGFR) or CD20. 
As described in chapter 1.2 gene modification of HSPCs is often achieved by ex vivo 
transduction with lentiviral vectors pseudotyped with VSVG due to their broad tropism 
(Cartier et al., 2009; Aiuti et al., 2013; Biffi et al., 2013). A receptor targeted 
transduction approach would allow gene modification of specific subsets of HSPC 
including very primitive cells. In bone marrow, cord and mobilized peripheral blood 
the frequency of true HSCs capable of self-renewal is limited to estimated 0.01-0.1% 
of total nucleated cells (Baum CM et al., 1992; Hao QL et al., 1995). During the 
differentiation process of HSCs into more committed progenitor cells and finally into 
mature cells of a defined lineage, the ability of self-renewal is lost. Over the last 
years, lots of effort was put into the identification of HSC surface markers in mouse 
and human that would allow a highly purified enrichment of HSCs. So far, the 
expression pattern of human HSCs includes CD34+ CD133high, CD90+, CD38-/low and 
CD45RA- (Civin CI et al., 1984; Terstappen et al., 1991; Baum CM et al., 1992; 
Miraglia et al., 1997; Yin et al., 1997; Majeti et al., 2007). The expression of these 
surface proteins changes during the differentiation process (Figure 3) and facilitates 
the distinction of different hematopoietic cell subsets. The surface expression pattern 
defining HSC in mouse and human differs. For murine HSCs CD105 is a well-
established marker  (Chen et al., 2002; Chen et al., 2003; Roques et al., 2012). 
There are few reports that CD105 is also present on a subset of human HSCs 
demonstrating that CD34+CD105+ cells show higher long-term culture-initiating cell 
frequency than the CD105- population (Pierelli et al., 2000; Pierelli et al., 2001). 
CD105 or endoglin is a component of the transforming growth factor- (TGF-) 
complex (St-Jacques et al., 1994; Warrington et al., 2005) and is involved in the TGF-
 signaling pathway, but it is suggested that it has further functions such as being 
involved in angiogenesis (Li et al., 1999). CD105 is mainly expressed on activated 
endothelial cells, but is also expressed on other cell types such as activated 
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macrophages,  mesenchymal stem cells (Lin et al., 2013) or progenitor endothelial 
cells (Nassiri et al., 2011). 72% of the sequence and expression profile between 
mouse and human is conserved (Letamendía et al., 1998) suggesting that CD105 
plays an underrated role in the definition of human HSCs.  
 
 
Figure 3: Hematopoietic hierarchy and phenotypic markers associated with HSCs. HSCs are 
defined by the ability of self-renewal and differentiation capacity. During the differentiation process into 
multipotent and oligopotent progenitor cells, HSCs lose their potential for self-renewal. The various 
subpopulations are defined by the expression of the indicated surface proteins. HSC, hematopoietic 
stem cell; MPP, multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid 
progenitor; MEP, megakaryocyte/erythrocyte progenitor; GMP, granulocyte/macrophage progenitor; 
EP, erythrocyte progenitor; MkP, megakaryocyte progenitor; GP, granulocyte progenitor; MacP, 
macrophage progenitor; Pro-DC, dendritic cell progenitor; Pro-B, B-cell progenitor; Pro-T, T-cell 
progenitor and Pro-NK, natural killer cell progenitor.  
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1.7 Objective 
Restricting gene delivery to therapeutic relevant cells will take in vivo gene therapy 
one step further. One aim of this thesis was the side by side comparison of LVs and 
AAV vectors using an identical receptor for cell entry. LV and AAV targeting Her2/neu 
were chosen, since both vectors present the same targeting ligand on the particle 
surface, namely the DARPin 9.29, and were well characterized before (Münch et al., 
2011; Münch et al., 2013). First, functional and genomic titers of both vector types 
had to be determined. While functional titers were assessed by transduction of Her2+ 
cells, a qPCR method that allows quantification of genomic titers of both vector types 
in parallel was established. In a next step, transduction efficiencies of Her2-AAV and 
Her2-LV were compared in vitro and in vivo. For the latter, luciferase expression was 
monitored in a subcutaneous tumor mouse model after systemic administration of 
either Her2-LVluc or Her2-AAVluc by in vivo imaging. In addition, distribution of the 
targeted vector particles was analyzed in a mouse model at early time points after 
vector injection. This first side by side comparison between lentiviral and AAV vectors 
using the identical cell entry receptor provides insight into performance, distribution 
and applicability of receptor-targeted lentiviral and AAV vectors.  
For genetic modification of HSPCs, LVs are mainly used due to their ability to 
integrate into the host’s genome ensuring long-term transgene expression. The 
second part of this thesis investigated the option to transduce a very primitive long-
term repopulating subpopulation of human CD34+ cells. Few studies suggested that 
CD105 is expressed on human HSCs (Pierelli et al., 2000; Pierelli et al., 2001). 
Therefore, the applicability of CD105 as a potential HSC marker was investigated. 
Expression levels of CD105 on HSCs were analyzed and the subpopulation 
expressing CD105 was defined in more detail. With the receptor-targeted CD105-LV 
that was previously shown to transduce specifically CD105 expressing endothelial 
cells the ability for gene transfer into unstimulated and stimulated CD34+ cells was 
investigated. Long-term transgene expression and differentiation capacity of CD105-
LV transduced cells was determined in vitro as well as in vivo and eventually 
compared to the commonly used VSVG-LV in a competitive setting.  
In summary, this thesis demonstrates the potential and possible applications of 
receptor-targeted gene transfer. 
  MATERIAL 
19 
 
2. MATERIAL AND METHODS 
2.1 Material 
2.1.1 Equipment 
Name  Model  Manufacturer  
Bacteria incubator shaker  Innova™ 4200  New Brunswick Scientific  
Cell incubator  BBD6220  Heraeus, Thermo Scientific 
Cell seperator autoMACS®  Pro 
Separator 
Miltenyi Biotec 
Cell sorter  BD FACSAria™ III  Becton Dickinson 
Centrifuge  Multifuge X3, 
Multifuge 3  
Heraeus, Thermo Scientific 
Flowcytometer  MACSQuant Analyzer Miltenyi Biotec  
Flowcytometer  LSRII  Becton Dickinson  
Fluorescence microscope  Axiovert 200  Zeiss  
Gel electrophoresis system  n/a  Bio-Rad  
Gel electrophoresis system  Model B3 Owl Separation Systems 
Homogenizer FastPrep®-24 
Instrument 
MP Biomedicals 
HPLC system  Smartline  Knauer  
in vivo imaging system  IVIS Spectrum  PerkinElmer  
Laminar Flow Cabinet Class II  SterilGARD® III  The Baker Company  
Light microscope  Axiovert 25  Zeiss  
LightCycler  LightCycler®  Roche  
Micropipettes  Research plus®  Eppendorf  
Microplate reader  THERMOmax  Molecular Devices  
Multichannel pipettes  Finnpipette F2  Thermo Scientific  
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Pipetboy  Accu-jet®  Brand  
Spectrophotometer  NanoDrop 2000c  Thermo Scientific  
Table-top processor  Curix 60™  Agfa  
Thermo cycler  PTC 200  MJ Research  
Ultracentrifuge  Optima™ L-70k  Beckman Coulter  
 
 
 
2.1.2 Kits 
Name  Supplier 
DNeasy Blood and Tissue Kit Qiagen 
96-DNeasy Blood and Tissue Kit Qiagen 
RNeasy Mini Kit Qiagen 
MAXIscript Kit Invitrogen 
Transcriptor First Strand cDNA Synthesis Kit Roche 
CD34 MicroBead Kit, human Miltenyi Biotec 
CD105 MicroBead Kit, human Miltenyi Biotec 
CD34 MultiSort Kit, human Miltenyi Biotec 
FastStart DNA MasterPLUS SYBR Green I Roche Diagnostics 
ABsolute QPCR ROX Mix Thermo Scientific 
GeneJET Gel Extraction Kit Thermo Scientific 
EndoFree Plasmid Maxi Kit Qiagen 
Jetstar 2.0 Maxi Kit Genomed 
Jetstar 2.0 Giga Kit Genomed 
JETStar NoEndo Jetfilter Giga Kit  Genomed  
RETROtek HIV-1 p24 Antigen ELISA  ZeptoMetrix  
pGEM®-T Easy Vector System Promega 
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2.1.3 Buffers and chemicals 
 
Name  Composition/Supplier  
AAV lysis buffer  50 mM Tris-HCl, 150 mM NaCl in PBS  
BTPE 10 mM PIPES, 30 mM Bis-Tris, 10 mM EDTA, pH 6,5 
DEPC H2O 0.1 % DEPC in H2O, Paul-Ehrlich-Institut 
D-Luciferin  Perkin Elmer  
DNA loading buffer 6x  Thermo Scientific  
ELISA blocking buffer  PBS, 0.05% Tween-20, 3% BSA, 5% sucrose  
ELISA washing buffer  PBS, 0.05% Tween-20  
FACS washing buffer  2% FCS in PBS  
FACS fix buffer 1% formaldehyde in PBS  
FACS sorting buffer  10 mM HEPES, 2% FCS, 0.5 mM EDTA in PBS  
Freezing medium  90% FCS, 10% DMSO  
Glyoxal mix 6 ml DMSO, 2 ml 6 M glyoxal, 1.2 ml 10x BTPE, 0.6 ml 
80% glycerine, 0.2 ml ethidium bromide (10 mg/ml) 
Histopaque®-1077  Sigma-Aldrich  
OptiPrep™  Sigma-Aldrich  
PBS  Lonza  
PBS M/K  2.5 mM KCl, 1 mM MgCl2 in PBS  
PEI  18 mM polyethylenimine in H2O  
SDS running buffer  25 mM Tris, 192 mM Glycine, 1% SDS  
StemSpan™ CC100 Stem cell technologies 
TAE  40 mM Tris, 20 mM Acetic acid, 1 mM EDTA  
TBS-T  10 mM Tris pH 8.0, 150 mM NaCl, 0.1% Tween-20  
Thrombopoietin (TPO) Peptrotech 
TMB liquid substrate  Sigma-Aldrich  
  MATERIAL 
22 
 
TNE  25 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA  
Transfer buffer  48 mM Tris, 39 mM Glycine, 20% Methanol  
Triton X-100  Sigma-Aldrich  
Trypsin solution  PBS, 2 mM EDTA, 0.25% Trypsin-Melnick  
Tween-20  Sigma-Aldrich  
 
2.1.4 Antibodies 
Name  Application  Dilution Supplier 
α-AAV intact particle, mouse (A20) ELISA  1:4  Progen  
α-mouse-biotin, donkey  ELISA  1:25,000  Jackson 
ImmunoResearch  
Streptavidin-HRP  ELISA  1:500  Jackson 
ImmunoResearch  
α-Her2/neu-PE, mouse  FC  1:20  BD Pharmingen  
α-CD105-APC FC 1:10 Invitrogen 
α-CD34-FITC FC 1:10 Miltenyi Biotec 
α-CD34-PE FC 1:10 Miltenyi Biotec 
α-CD133-PE  FC 1:10 Miltenyi Biotec 
α-CD90-PEVio770 FC 1:10 Miltenyi Biotec 
α-mCD45-PE FC 1:10 Miltenyi Biotec 
α-hCD45-APC FC 1:10 Miltenyi Biotec 
α-CD3-PE FC 1:10 Miltenyi Biotec 
α-C19-PE FC 1:10 DAKO 
α-CD33-PE FC 1:10 BD Pharmingen 
α-CD38-FITC FC 1:10 Miltenyi Biotec 
FcR blocking reagent, human  FC  1:10  Miltenyi Biotec  
FC, flow cytometry; ELISA, enzyme-linked immunosorbent assay. 
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2.1.5 Oligonucleotides 
Name  Sequence (5’ – 3’) 
GFP-for  GCTACCCCGACCACATGAAG  
GFP-rev  GTCCATGCCGAGAGTGATCC  
luc2-for  TTCGGCTGGCAGAAGCTATG  
luc2-rev  GCTCGCGCTCGTTGTAGATG  
luc3-fw GTGGTGTGCAGCGAGAATAG 
luc3-rv 
luc3 probe 
CGCTCGTTGTAGATGTCGTTAG 
[6FAM]TTGCAGTTCTTCATGCCCGTGTTG[BHQ1] 
ivtr_GFP fw CGTGACCACCCTGACCTAC 
ivtr_GFP rv GCCGTCGTCCTTGAAGAAGATG 
ivtr_luc fw CTTCGAGATGAGCGTTCGGCTG 
ivtr_luc rv CCATGCTGTTCAGCAGCTCG 
 
2.1.6 Plasmids 
Name  Description  Source  
pCMV∆R8.91  HIV-1 packaging plasmid  U. Blömer  
(Zufferey et al, 1998)  
pSEW  HIV-1 transfer vector encoding GFP 
under control of the SFFV promoter  
M. Grez (Demaison et al, 
2002)  
pSEW-BFP HIV-1 transfer vector encoding BFP 
under control of the SFFV promoter 
T. Abel 
pS-luc2-W  HIV-1 transfer vector encoding 
luciferase under control of the SFFV 
promoter  
(Abel et al, 2013)  
pMD2.G  Encodes the VSV glycoprotein  D. Trono  
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pCG-Hmut-
αCD105 
encodes MV H
mut
18 fused to the 
αCD105-scAb 
(Anliker et al. 2010) 
pCG-F∆30  Encodes MV F with a truncated 
cytoplasmic tail of 30 aa under control 
of the CMV promoter  
(Funke et al, 2008)  
pCG-H
mut
∆18-
DARPin-9.29  
Encodes MV H
mut
18 fused to the 
Her2/neu-specific DARPin 9.29  
(Münch et al, 2011)  
pXX6-80  Adenoviral helper plasmid encoding 
E2A, E4 and VA  
H. Büning  
pscGFP-SFFV  Self-complementary AAV transfer 
vector encoding GFP under control of 
the SFFV promoter  
(Münch et al, 2013)  
pscluc2-SFFV  Self-complementary AAV transfer 
vector encoding luciferase under control 
of the SFFV promoter  
(Münch et al, 2013)  
pRC-VP2
KO
-
HSGP
mut 
 
Encodes the AAV2 rep and cap proteins 
with mutated VP2 start codon and the 
point mutations R585A and R588A  
H. Büning  
pDARPin-9.29-
VP2  
Encodes the Her2/neu-specific DARPin 
9.29 fused to the N-terminus of the 
AAV2 VP2 protein containing the point 
mutations R585A and R588A  
(Münch et al, 2013)  
pGEM-T7-GFP Encodes part of the egfp sequence 
under the control of the T7 promoter  
This thesis 
pGEM-T7-luc Encodes part of the luc sequence under 
the control of the T7 promoter 
This thesis 
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2.1.7 Bacterial strains and mammalian cells 
Name  Description  Source  
E. coli 
Top10  
Chemically competent bacterial strain  Life 
Technologies 
E. coli 
SURE  
Chemically competent bacterial strain (Stop Unwanted 
Rearrangement Events)  
Stratagene  
HEK-
293T  
Human embryonic kidney cell line, genetically 
engineered to express the SV40 T antigen  
ATCC  
CRL-11268  
SK-OV-3  Human ovarian carcinoma cell line  ATCC 
HTB-77  
 
2.1.8 Culture media 
Name  Description  Source  
Luria-Bertani (LB) 
broth  
1% tryptone, 0.5% yeast extract, 1% NaCl in 
H
2
O pH 7.2  
Paul-Ehrlich-
Institut  
S.O.C. medium  2% Tryptone, 0.5% yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl
2
, 10 mM MgSO
4
, 20 
mM glucose in H
2
O  
Invitrogen  
Dulbecco’s modified 
Eagle medium 
(DMEM)  
Supplemented with 10% FCS and 2 mM L-
glutamine as culture medium for HEK-293T  
Lonza  
McCoy’s medium  Supplemented with 10% FCS and 2 mM L-
glutamine as culture medium for SK-OV-3 cells  
Sigma-
Aldrich  
StemSpan™ Serum-
Free Expansion 
Medium (SFEM) 
Supplemented with 2 mM L-glutamine and 
0.5% Penicillin-Streptomycin-Fungizone mix as 
culture medium for human CD34+ cells 
 
 
Stem cell 
technologies 
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MethoCult GF 
H4434 medium 
Supplemented with 2 mM L-glutamine and 
0.5% Penicillin-Streptomycin-Fungizone mix as 
culture medium for human CD34+ cells in 
colony forming assays 
Stem cell 
technologies 
 
 
2.2 Methods of molecular biology  
2.2.1 Transformation of chemically competent bacteria 
Chemically competent E. coli Top10 or SURE bacteria were thawed on ice and 50 ng 
DNA or 2 µl of ligation reaction were added. After 30 min incubation on ice, bacteria 
were heated to 42°C for 45 sec and then immediately cooled on ice. 500 µl S.O.C 
medium was added. Bacteria were incubated for 30 min at 37°C and 600 rpm. 
Subsequently, bacteria were plated onto LB agar plates supplemented with the 
corresponding antibiotic and incubated overnight at 37°C or for 3 days at 25°C.  
 
2.2.2 Plasmid preparation 
Plasmid DNA from transformed bacteria was purified using the GeneJET Plasmid 
Miniprep Kit, EndoFree Plasmid Maxi Kit or JETStar NoEndo Jetfilter Giga Kit 
according to the manufacturer’s protocol. 4 ml, 250 ml or 2400 ml LB medium 
supplemented with the corresponding antibiotics were inoculated with a single 
bacterial clone and incubated overnight at 37°C. Cells were pelleted by centrifugation 
at 13,000 rpm (Miniprep, Multifuge 3) or  6,000 rpm (Maxiprep, Sorvall Rc26 plus) for 
15 min or at 4,500 rpm for 1 hour (Gigaprep, Multifuge 3)  The concentration of 
purified DNA was measured photometrically by NanoDrop 2000c. Plasmid 
preparations were analyzed by agarose gel electrophoresis (2.2.4) after enzymatic 
control digest (2.2.3).  
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2.2.3 Restriction of DNA 
All DNA restrictions were performed using restriction endonucleases from New 
England Biolabs according to the manufacturer’s instructions. 10 µg DNA were mixed 
with 10 U of the respective restriction enzyme under the required buffer conditions 
and incubated for 3 hours. For double digestions with enzymes requiring different 
buffer conditions, the optimal buffer for both enzymes was chosen. For digestions 
with different incubation temperatures, the restriction reactions were performed 
sequentially. Restriction samples were applied to agarose gel electrophoresis. If 
required, the desired DNA fragment was purified from the gel using the GeneJET Gel 
Extraction Kit (Thermo Scientific). 
 
2.2.4 Agarose gel electrophoresis 
Agarose gel electrophoresis allows the separation of DNA or RNA fragments 
according to their size. For the analysis of DNA, agarose powder was dissolved in 
TAE buffer by heating. 50 µg/ml ethidium bromide that intercalates into DNA strands 
was added to the agarose solution. After polymerization on a gel tray, DNA samples 
were mixed with 6x loading buffer and transferred into the gel pockets. 
Electrophoresis was performed at 80-100 V in a Bio-Rad WIDE MINI-SUB chamber. 
Separation of DNA fragments was analyzed under UV light and compared to a 2-log 
ladder (New England Biolabs).  
For visualization of RNA, agarose powder was dissolved in BTPE to a final 
concentration of 1.5%. Polymerization took place on a gel try. 2 µl of RNA were 
mixed with 10 µl of glyoxal mix containing ethidium bromide. RNA samples as well as 
the RibuRuler High Range RNA ladder (Life Technologies) were incubated at 55°C 
for 30 min and then cooled on ice for 5 min. 5x loading buffer was added and the 
samples loaded into the gel pockets. Electrophoresis was performed at 120 V for 2 
hours in a Owl Separation Systems chamber with buffer recirculation. RNA fragments 
were visualized under UV light.  
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2.2.5 Isolation of DNA from agarose gels 
Gel pieces containing the DNA fragments of interest were cut out of the agarose gel 
and DNA was isolated using the GeneJET Gel Extraction Kit (Thermo Scientific) 
according to the company’s protocol.   
 
2.2.6 Isolation of genomic DNA 
Genomic DNA from AAV vector stocks was isolated using the DNeasy Blood and 
Tissue Kit (Qiagen), total DNA from tissue was purified using the 96-DNeasy Blood 
and Tissue Kit (Qiagen) according to the manufacturer’s instructions. For 
quantification of AAV genomic titers 10 µl of the AAV vector stocks were diluted with 
190 µl PBS and applied to isolation followed by qPCR. 10 mg of spleen and 20 mg of 
other tissue was used for DNA isolation. Purification of total DNA included treatment 
of the samples with RNase.  
 
2.2.7 Isolation of total RNA 
RNA from lentiviral vector stocks and tissue was isolated using the RNeasy Mini Kit 
(Qiagen) according to the company’s protocol. 10 µl of LV were used for subsequent 
quantification of genomic titers.  10 mg of homogenized spleen and 20 mg of other 
homogenized tissue were applied to RNA purification.  An on-column DNase I digest 
was included into both isolation procedures.   
 
2.2.8 Generation of RNA standard 
For the generation of the RNA standard for qPCR, sequences of the transgenes luc 
or egfp were amplified by polymerase chain reaction and ligated into the pGEM®-T 
Easy vector (Promega) to introduce a T7 promoter upstream of the gene of interest 
according to the manufacturer’s instruction. The resulting plasmids were linearized by 
a single cut after the gene of interest. The linearized plasmid served as template for 
the in vitro transcription of RNA. RNA was generated using the MAXIscript Kit 
(Invitrogen) according to manufacturer’s instructions including a DNase I digestion. 
Then, RNA was purified by two rounds of phenol-chloroform extraction and one 
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chloroform extraction, followed by two sodium acetate/ethanol precipitations. The 
purified RNA pellet was resuspended in DPEC H2O and analyzed by agarose gel 
electrophoresis. The RNA concentration was determined photometrically by 
NanoDrop 2000c and adjusted to 1x1011 RNA molecules/µl.  
 
2.2.9 Reverse transcription 
In vitro transcribed RNA and RNA from lentiviral vector stocks or tissue was reverse 
transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche)                    
according to the manufacturer’s protocol. 1 µl of RNA standard, 3 µl of LV RNA and 
maximum amounts (up to 5 µg) of total RNA from tissue were incubated with specific 
primers for 10 min at 65°C to denature secondary RNA structures. The samples were 
cooled on ice, before reverse transcriptase buffer, enzymes and deoxynucleotide mix 
were added. After 30 min at 55°C, the reverse transcriptase was inactivated by 
heating to 85°C for 5 min. The samples were placed on ice and applied to qPCR 
within 2 hours or stored at -20°C.   
 
2.2.10 Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) allows the amplification and quantification of a 
specific DNA sequence by the use of a fluorescence dye. qPCR was used to 
determine genomic titers of lentiviral and AAV vector stocks as well as vector 
amounts in tissue. For the quantification of genomic titers of lentiviral and AAV vector 
stocks, the SYBR Green containing PCR mix FastStart DNA MasterPLUS SYBR Green 
I (Roche) was used. SYBR Green intercalates into double stranded DNA fragments. 
For quantification of vector genomes in tissues, a primer/probe set specific for the 
transgene was used in combination with the ABsolute QPCR ROX Mix (Thermo 
Scientific) to enhance the signal specificity. At the end of each amplification cycle the 
fluorescence was measured, whereby an increased fluorescence signal correlated 
with an increase of the PCR product. Comparison of the crossing points obtained 
from unknown samples with that of a standard of known concentration, allowed 
absolute quantification of vector genome content in the samples. As standard for 
quantification of AAV genomes, a 10-fold serial dilution of the AAV transfer plasmid 
was used. 10-fold serial dilutions of the RNA standard which was obtained by in vitro 
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transcription were reverse transcribed. The cDNA served as standard to determine 
the amount of lentiviral RNA in samples. qPCR was performed in either the 
LightCycler 1.2 or the LightCycler 480 using the conditions specified below. 
 
Table 1: qPCR reaction using SYBR Green 
Component  Volume 
H2O, nuclease free 14 μl 
Primer for (20 pmol/μl) 0.5 μl 
Primer rev (20 pmol/μl) 0.5 μl 
FastStart DNA MasterPLUS SYBR Green I (1a+1b) 4 μl 
Template DNA or cDNA (isolated from AAV or lentiviral vectors) 1 μl 
 
 
Table 2: qPCR program using SYBR Green 
Initial denaturation 95°C 10 min 
Quantification  (40 cycles)  95°C 10 sec 
 64°C 4 s*, 5 s# 
 72°C 7 s*, 10 s# 
Melting curve 95°C 0 s 
 67°C 10 s 
 95°C 0 s 
*egfp transferring vectors, # luc transferring vectors 
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Table 3: qPCR reaction using primer/probe set 
Component  Volume 
H2O, nuclease free 6-10 μl 
Primer for (20 pmol/μl) 0.5 μl 
Primer rev (20 pmol/μl) 0.5 μl 
Probe 0.5 μl 
Absolute QPCR ROX Mix (2x) 12.5 μl 
Template DNA or cDNA  1-5 μl 
 
Table 4: qPCR program using primer/probe set 
Initial denaturation 95°C 15 min 
Quantification  (40 cycles)  95°C 15 sec 
 64°C 30 s 
 72°C 30 s 
 
2.2.11 Polymerase chain reaction 
To amplify parts of the sequences of either gfp or luc and introduce specific 
restriction sites to the corresponding DNA fragments, PCR was performed using the 
primers ivtr_GFP fw and ivtr_GFP rv or ivtr_luc fw and ivtr_luc rv and the Taq DNA 
polymerase (5 Prime) according to the manufacturer’s protocol. Thereby, adenine 
overhangs at the 3' ends of the PCR products are introduced for efficient ligation into 
the pGEM®-T Easy (Promega) vector. The cycling details are specified below. 
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Table 5: PCR program 
Initial denaturation 95°C 2 min 
Amplification  (20 cycles)  95°C 30 s 
 62°C 30 s 
 68°C 12 s 
Final extension time 68°C 10 min 
 
2.2.12 Enzyme-linked immunosorbent assay (ELISA) 
Numbers of physical particles within lentiviral and AAV vectors stocks were 
determined by ELISA. Quantification of LV particle numbers was based on the 
amount of p24 protein in lentiviral vector stocks. p24 protein was quantified using the 
RETROtek HIV p24 antigen ELISA kit (Zeptometrix) according to the company’s 
protocol.  
For AAV capsid quantification, Maxisorp immunoplates were coated with serial 
dilutions of AAV vector stocks over night at 4°C. The following day, plates were 
washed three times with ELISA washing buffer and blocked with ELISA blocking 
buffer for 2 hours at room temperature. The -AAV2-capsid antibody was diluted 1:4 
in blocking buffer and added to the bound vector particles for one hour. After three 
washing steps, the-mouse Biotin-conjugated secondary antibody was incubated on 
the samples for one hour at room temperature. The plate was washed again and 
then incubated with streptavidin-HRP diluted in ELISA blocking buffer. The plate was 
washed three times with ELISA washing buffer and three times with water. For 
detection of coated capsids, the TMB liquid substrate system and a microplate reader 
were used according to the manufactures’ instructions. A previously analyzed vector 
preparation served as standard.  
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2.3 Cell culture and virological methods 
2.3.1 Cultivation of cell lines 
Cells were cultivated in the adequate medium (2.1.8) in a cell culture incubator at 
37°C, 5% CO2 and 90% humidity. Cells were splitted twice a week. Adherent cells 
were washed with PBS and detached using 0.25% trypsin solution. The adequate 
fraction of the cell suspesion was transferred to a new cell culture flask and fresh 
medium was added. Cell lines were checked for mycoplasma contamination by PCR 
regularly.  
 
2.3.2 Freezing and thawing of cultured cells 
Adherent cell lines were detached as described in 2.3.1, resuspended in cell culture 
medium and centrifuged at 800 rpm, 4°C for 4 min. The cell pellet was resuspended 
in cold freezing medium, aliquoted and frozen at -80°C using a 5100 Cryo Freezing 
container (Nalgene). The following day, cells were transferred to the gas phase of 
liquid nitrogen for long-term storage.  
Frozen cells were thawed in a 37°C water bath and transferred into pre-warmed 
culture medium in a fresh cell culture flask. The next day, medium was refreshed.  
 
2.3.3 Production and purification of vector particles 
Lentiviral and AAV vector particles were produced by transient transfection of HEK-
293T cells by polyethylenimine (PEI). DNA and PEI form positively-charged 
complexes that bind to the cell surface. DNA/PEI is endocytosed and released into 
the cell cytoplasm. 1.4x105 HEK-293T cells per cm2 cell culture vessels were seeded. 
The following day, medium was replaced with DMEM supplemented with 15% FCS 
and 3.2 mM glutamine. 0.2 mg DNA/cm2 and 0.8 ml PEI/cm2 were diluted in DMEM 
and vortexed. Both solutions were combined and vortexed thoroughly. The DNA/PEI 
mixture was incubated for 20 min at room temperature and then added to the cells. 
After 24 hours, medium was refreshed.  
For the production of LVs, lentiviral vector particles were harvested from the 
supernatant 48 hours post transfection. The supernatant was collected and filtered 
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through a 0.45 µm PTFE filter. Vector particles were purified and concentrated by 
centrifugation either at 100,000 x g for 3 hours at 4°C or at 4,400 x g for 24 hours at 4 
°C both through a 20% sucrose cushion. LVs were resuspended in PBS, aliquoted 
and stored at -80°C.  
AAV vector producer cells were scraped off the cell culture dish and spun down at 
1,000 rpm for 7 min. Cell pellets were resuspendend in AAV lysis buffer. After three 
freeze/thaw cycles, cell lysate was incubated with benzonase at 37°C for 30 min. Cell 
debris were removed by centrifugation for 20 min at 3700 x g and 4°C. For 
purification by density centrifugation, vector containing supernatant was diluted with 
PBS M/K and transferred to a Quick-Seal® ultracentrifugation tube (Beckman 
Coulter). The supernatant was underlain consecutively with 9 ml 15%, 6 ml 25%, 5 ml 
40% and 6 ml 60% OptiPrep™. After 2 hours centrifugation at 63,000 and 4°C, AAV 
vectors were recovered from the 40% OptiPrep™ phase, aliquoted and stored at -80°C.  
 
2.3.4 Transduction of adherent cell lines and titration of vectors 
The day before transduction, 8x103 cells were seeded into a single well of a 96-well 
plate. For titration, vector stocks were diluted in medium (2-fold serial dilutions of 
AAV vectors, 10-fold serial dilutions of LVs) and added to the cells. The percentage 
of GFP expressing cells was determined by flow cytometry 72 hours after 
transduction with LVs and 96 hours after transduction with AAV vectors. For titer 
calculations fractions between 2 and 20% GFP+ cells were considered. In addition, 
for the quantification of functional AAV titers, the cell proliferation rate was taken into 
account. For the transduction of cell lines, the required amount of vectors was diluted 
in medium and added to the cells. Analysis of the percentage of GFP+ cells was 
performed 72, respectively, 96 hours post transduction.  
 
2.3.5 Isolation of human CD34+, respectively, CD105+ cells from mobilized 
peripheral blood 
G-CSF mobilized peripheral blood was obtained from stem cell donations with written 
consent of the donors and in accordance with the ethical standards of the 
responsible committee on human experimentation (IRB permit 329/19). CD34+ cells 
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were isolated by positive selection using -CD34 microbeads (Miltenyi Biotec) 
according to manufacturer’s instructions. CD34 specific antibodies conjugated to 
magnetic beads were incubated with the blood at 4°C for 30 min, labeling CD34+ 
cells magnetically. Then, the cells were applied to a column in a magnetic field, 
retaining the magnetically labeled CD34+ cells while unlabeled cells were washed off 
the column. After releasing the column from the magnetic field, CD34+ cells were 
eluted. Magnetically labeled antibodies remained bound to the cell surface. Cells 
were pelleted at 1,200 rpm for 5 min and transferred into stem cell culture medium 
(2.1.8). CD105+ cells were purified from mobilized peripheral blood using CD105 
microbeads (Miltenyi Biotec) as described for CD34+ cells, however, the incubation 
time at 4°C was 15 min.  
For isolation of CD34+ cells with subsequent purification of CD105+ cells, the CD34 
MultiSort Kit (Miltenyi Biotec) was used according to the company’s protocol. The 
principal is the same as for the isolation of CD34+ cells from mobilized peripheral 
blood only, but includes a step for the release of the magnetic beads from the primary 
antibodies and a second magnetic labeling of the eluted cells from the first 
purification round. The -CD34 antibodies that were bound to the cells during the first 
labeling remained bound to the cells, but only the magnetic beads were released 
from the cell. The mircobeads conjugated to the -CD105 antibodies of the second 
magnetic labeling remained bound to the cell surface as well.  
 
2.3.6 Cultivation and stimulation of HSPCs 
Unstimulated CD34+ cells were cultured in StemSpan serum free expansion medium 
(Stemcell Technologies) supplemented with 0.5% Penicillin-Streptomycin-Fungizone 
Mix (PromoCell) and 2 mM glutamine. 5x104 cells were seeded per well of a 96-well 
plate. For stimulation of the cells the medium was supplemented with StemSpan 
CC100 cytokine cocktail (Stemcell Technologies) and 2 µg/mL thrombopoietin (TPO) 
(Peprotech). After 24 hours, the cytokine-free medium of unstimulated cells was 
replaced by cytokine containing medium. CD105+ cells from mobilized peripheral 
blood were cultivated in the same way.  
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2.3.7 Transduction of HSPCs 
5x104 CD34+ cells/well were transduced in 96-well plates by spinfection at 1,200 rpm 
and 32°C for 90 min. CD34+ cells for animal experiments were transduced in 24- or 
12-well plates in the correlating cell density. Transduction of cells took place either 
immediately after isolation (unstimulated) or after overnight incubation in cytokine 
containing medium (stimulated). LVs were diluted in the corresponding medium and 
added to the cells. The final transduction volume was filled up to 250µl/well of a 96-
well plate. Seventy-two hours post transduction, GFP expression was analyzed by 
flow cytometry. 
 
2.3.8 Colony forming assay 
The colony forming assay (CFA) is used to enumerate and assess colonies derived 
from myeloid multipotential progenitors and committed progenitors of the erythroid, 
monocyte and granulocyte lineages. Hematopoietic progenitor cells are applied to 
semi-solid methylcellulose medium supplemented with growth factors and cytokines 
that allows the progenitors to proliferate and differentiate into colonies of mature cells 
(Pereira et al., 2007). 1.5x103 transduced or untransduced primary human CD34+ 
cells were transferred into 3 ml MethoCult GF H4434 medium (Stemcell 
Technologies, Cologne, Germany) and plated in triplicates. After 10 days at 37°C and 
95°C humidity, total and GFP+ colonies were counted and morphologically classified 
by fluorescence microscopy.  
 
2.3.9 Analysis of cells by flow cytometry and fluorescence activated cell 
sorting 
Flow cytometry is a laser-based technique that allows, based on scattered and 
emitted light, the characterization of cells on the basis of their size, morphology and 
fluorescence intensity. Additionally, expression of specific proteins can be assessed 
by binding of fluorophore labeled antibodies. Adherent cells were detached by 
incubation with PBS-Trypsin (PBS, 100mM EDTA, 0.25% Trypsin-Melnick). Cells 
were washed once with FACS washing buffer by centrifugation at 800 rpm for 4 min. 
Then, cells were either fixed immediately using FACS fix buffer or stained with 
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antibodies (2.1.4). After antibody staining, cells were washed once and fixed using 
FACS fix buffer. Primary human or murine cells were washed once with FACS 
washing buffer by centrifugation at 1,200 rpm for 4 min. Afterwards, cells were 
stained (2.1.4) or fixed with FACS fix buffer. Samples were measured using either the 
BD LSR II SORP (Becton-Dickinson) or the MACSQuant® Analyzer 10 (Miltenyi 
Biotec) and analyzed using the FCS Express V4 software (De Novo software).  
For fluorescence activated cell sorting (FACS) of CD105+ cells, cells from mobilized 
peripheral blood were washed with PBS, stained with -CD105-APC antibody and 
washed again. CD105 high expressing cells were collected in sorting buffer, washed 
once and resuspended in StemSpan serum free expansion medium supplemented 
with 0.5% Penicillin-Streptomycin-Fungizone Mix and 2 mM glutamine. 
 
2.3.10 Annexin V/propidium iodide staining 
For determination of apoptotic and necrotic cells, cells were stained with annexin V 
and propidium iodide (PI). Annexin V binds to phosphatidylserine that translocates to 
the extracellular cell membrane upon apoptosis induction. The cell membrane of late 
apoptotic and necrotic cells becomes permeable which enables PI to intercalate into 
the DNA. Thereby, early and late apoptotic/necrotic cells can be distinguished. 
CD34+ cells transduced with either CD105-LVGFP or VSVG-LVGFP were washed once 
with annexin binding buffer and then resuspended in annexin binding buffer. Cells 
were mixed with annexin V-APC (BD Bioscience) and incubated for 15 min at room 
temperature in the dark. After another washing step, cells were resuspended in 
annexin binding buffer. PI (Miltenyi Biotec) was added to the samples immediately 
before cells were analyzed by flow cytometry.  
 
2.3.11 Competition assay 
For the competition of CD105-LV with soluble CD105 protein, vector particles were 
incubated with increasing amounts of the extracellular domain of CD105 protein 
(sCD105) at 37°C for 30 min. Then, CD34+ cells were transduced with the vector-
protein mixtures by spinfection. Seventy-two hours post transduction, GFP 
expression was determined by flow cytometry.  
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2.3.12 Serum stability assay 
Serum from mice was collected and pooled. One part of the serum was heat-
inactivated by incubation at 56°C for 30 min and then cooled on ice briefly. Heat-
inactivated and non-heat-inactivated serum was added to Her2-LVGFP and Her2-
AAVGFP in increasing concentrations and incubated at 37°C for 30 min. Afterwards, 
SK-OV-3 cells were transduced with the serum-vector mixtures. Ninety-six hours post 
transduction, GFP expression was determined by flow cytometry.  

2.3.13 Expression of soluble CD105 protein 
Soluble CD105 (sCD105) protein was used for a competition assay with CD105-LV. 
The recombinant protein was expressed in HEK-293T cells, following PEI 
transfection of cells with the plasmid encoding the extracellular domain of CD105, 
fused to a Fc-tag (kindly provided by Irene Schneider and Gundula Braun). After 24 
hours, the transfection medium was replaced with Panserin A medium. Forty-eight 
and 72 hours post transfection sCD105 containing supernatant was collected, filtered 
through a 0.45 mm filter and stored at 4°C. sCD105 was purified from the 
supernatant by HPLC purification by binding of the Fc-tag to protein A. Purified 
protein was dialyzed against PBS at 4°C for 8 hours and additional 12 hours.  

2.3.14 Isolation of blood, BM and spleen cells from mice 
For the isolation of BM cells, tissue was removed from femur and tibia. The bones 
were disinfected with 70% ethanol and the joints on both ends were cut off. The BM 
was flushed out of the bones using PBS, a 5 ml syringe and a 27G cannula. BM cells 
were resuspended in PBS and passed through a 40 µm cell strainer. After 
centrifugation for 10 min at 1,200 rpm, remaining red blood cells were removed using 
the BD Pharm Lyse™ lysing solution (BD Bioscience) according to the 
manufacturer’s instructions. Cells were washed once with PBS, resuspendend in 
FACS washing buffer and stained with antibodies for flow cytometry analysis.  
For the isolation of splenocytes, the spleen was transferred into a cell culture dish 
containing PBS and mashed using the plunger of a 5 ml syringe. The cell suspension 
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was passed through a 40 µm cell strainer. Afterwards, it was continued as for the 
preparation of BM cells.  
Blood collected from mice was washed once with PBS. BD Pharm Lyse™ lysing 
solution (BD Bioscience) was used for erythrocyte lysis according to the company’s 
protocol. Cells were washed with PBS, resuspended in FACS wash buffer and then 
stained with antibodies for flow cytometry analysis.  

2.4 Experimental mouse work 
Animal experiments were performed according to the German animal protection law 
and are approved by the responsible institutional ethical committee. 
 
2.4.1 Repopulation of NSG mice with human CD34+ cells 
5-6 week old NOD-scid IL2R-/- mice were sublethally irradiated at 1.8 or 2 Gy. After 
4 hours, 0.5-1.7x106 transduced or untransduced CD34+ cells purified from mobilized 
peripheral blood were injected via the tail vein using a 30G cannula. Seven days 
before to 7 days after the cell transplantation, mice received 2.5% bytril in their 
drinking water.  
 
2.4.2 Subcutaneous injection of SK-OV-3 cells 
SK-OV-3 cells were cultured and detached as described above and centrifuged at 
1,200 rpm for 7 min. Afterwards, cells were washed once with PBS. 1x107 cells were 
resuspended in 100 µl PBS and aliquoted. 6-7 week old athymic nude Fox mice 
(Harlan) were anesthetized with 2.5% isofloran using a XGI-8 Gas Anestesia System 
(Caliper Life Sciences). Tumor cells were gently vortex before they were injected 
subcutaneously into the right flank using a 23G cannula. During the procedure mice 
were kept on a heating plate.  
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2.4.3 Administration of vector particles 
Concentrated and purified lentiviral and AAV vectors were diluted in PBS to the 
anticipated vector concentration. Vector suspensions were administered by 
intravenously injection using a 30G cannula.   
 
2.4.4 In vivo imaging 
In vivo imaging allows visualization of bioluminescence signals in a non-invasive way. 
Mice were injected intraperitoneally with 150 mg D-Luciferin/kg body weight (Perkin 
Elmer) using a 30G cannula. After 5 minutes, mice were anesthetized with 2.5% 
isofloran using a XGI-8 Gas Anestesia System (Caliper Life Sciences). Then, mice 
were transferred to the IVIS® Imaging System 200 (Caliper Life Sciences) and 
imaging signals were analyzed 9 minutes after substrate injection. Analysis of the 
data was performed using the Living Image 4.2 software (Caliper Life Sciences).
  RESULTS 
41 
 
3. RESULTS 
This thesis describes in its first part the side by side comparison of Her2/neu-targeted 
lentiviral and AAV vectors. Quantification of genomic, physical and functional titers of 
Her2-LV and Her2-AAV revealed that approximately 10-fold more functional particles 
than genomes are present in the analyzed Her2-AAV vector stocks which was also 
confirmed in vitro and in a xenograft tumor mouse model.  
Making use of the lentiviral vector’s capability to integrate into the host cell genome, 
the second part of this thesis describes an approach for targeted gene transfer into 
human hematopoietic stem cells. Once surface expression of CD105 on HSCs was 
confirmed, transduction of CD34+ cells using the CD105-targeted LV was 
investigated. Transduced cells showed long-term stable gene expression and 
superior engraftment potential in NSG mice compared to VSVG-LV transduced cells. 
Thereby, CD105 was confirmed to serve as phenotypic marker on early HSCs.  
 
3.1 Side by side comparison of receptor targeted lentiviral and AAV 
vector stocks 
Gene delivery by receptor targeted viral vectors restricts gene transfer to specific cell 
populations. For gene delivery into Her2/neu positive cells, receptor targeted AAV 
and lentiviral vectors were generated and well characterized (Münch et al., 2011; 
Münch et al., 2013). Both vectors display the DARPin 9.29, directed against the 
tumor antigen Her2/neu. Her2/neu is a type 1 receptor tyrosine kinase belonging to 
the epidermal growth factor family and is over-expressed on various cancer cells 
such as pancreatic, ovarian and breast cancer cells (Slamon et al., 1987; Slamon et 
al., 1989; Hall et al., 1990). Since both vectors mediate gene transfer via the same 
targeting ligand, in particular the DARPin 9.29, Her2-LV and Her2-AAV were 
compared side by side in regard to titers, transduction efficiencies and biodistribution 
in vivo. 
 
 
 
  RESULTS 
42 
 
3.1.1 Quantification of titers of lentiviral and AAV vector stocks 
First, genomic, physical and functional titers of Her2-LV and Her-AAV were 
quantified. 
 
3.1.1.1 Genomic titers 
To quantify genome copies within vector stocks a suitable quantitative real-time PCR 
(qPCR) method was established. Sequences within the transgenes, egfp or 
luciferase (luc), were selected as amplification target. This allows determination of 
genomic titers of LV and AAV vector stocks within one single qPCR run, avoiding 
run-to-run variabilities. Absolute quantification by qPCR requires internal standards. 
For determination of AAV vector titers,  the DNA standard was generated by serial 
dilution of the transfer plasmid (Münch et al., 2013) as described previously (Rohr et 
al., 2002). Genomic titers of LVs were quantified by use of a RNA standard that was 
generated by in vitro transcription and reverse transcribed in parallel with the lentiviral 
RNA.  
 
3.1.1.1.1 Establishing the qPCR 
For quantification of genomic titers of LVs by qPCR, a RNA standard was generated 
by in vitro transcription. As target sequence for amplification by qPCR, sequences 
within the transgene (egfp or luc) were chosen since these are present in both Her2-
LV and Her2-AAV vectors. By cloning of the adequate DNA fragment from either 
pSEW (egfp) or pS-luc-W (luc) into the pGEM-T easy plasmid (Promega), a T7 
promoter was introduced upstream of the target sequence that was then used for the 
generation of the RNA standard by in vitro transcription using the MAXIscript Kit 
(Invitrogen) according to manufacturer’s instructions. In a first approach, the 
generated RNA was purified by DNase I digest only, followed by two rounds of 
sodium acetate/ethanol precipitation. In the next approach, two rounds of phenol-
chloroform and one additional chloroform extraction were included after the DNase I 
digest. The purity of RNA was confirmed by agarose gel electrophoresis (Figure 4A). 
The concentration of the RNA standard was adjusted to 1011 RNA molecules/µl. 
Serial 10-fold dilutions of the RNA standard were applied to reverse transcription 
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using specific primers. As a control, RNA from each dilution step was applied to the 
reaction missing the reverse transcriptase (-RT). Afterwards, cDNA of the RNA 
standard samples +/- RT were amplified by qPCR using SYBR green (Figure 4B).  
 
Figure 4: RNA standard for quantification of genomic lentiviral titers generated by in vitro 
transcription. (A) RNA standards after purification on glyoxal-agarose gel. (B) Agarose gel of PCR 
products of reverse transcribed luc RNA standard. G+, GFP RNA standard; L+, luc RNA standard; G-, 
L- , RNA standard negative controls: no enzyme present in in vitro transcription reaction.  
 
cDNA from 107 to 1011 reverse transcribed RNA molecules showed fluorescence 
signals in a linear range, whereas less than 107 RNA molecules, which is equivalent 
to approximately 1pg RNA, led to amplification of unspecific sequences (Figure 5). In 
addition, only serial 10-fold dilutions from 1011 to 107 molecules led to differences 
between two crossing points that were close by the theoretically expected difference 
of 3.32, assuming the efficiency of the qPCR is 100%. Furthermore, -RT-samples 
showed differences to the crossing points of their corresponding +RT-sample from 15 
to 19 cycles, when the RNA standard was phenol-chloroform extracted after in vitro 
transcription (Figure 5). This correlates to a negligible residual DNA contamination of 
104.5 to 106 DNA molecules, originating from the preparation of the RNA standard. In 
contrast, without additional phenol-chloroform extraction the differences between 
+RT and –RT-samples were only about 5 to 11 cycles. Therefore, the linear range 
from 1011 to 107 RNA molecules allowed reliable quantification for LV RNA using the 
phenol-chloroform extracted RNA standard. 
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Figure 5: Quantitative real-time PCR of RNA standard. RNA standard was generated by in vitro 
transcription. A serial dilution of the RNA standard molecules was reverse transcribed and analyzed by 
qPCR. (A) RNA standard which was additionally purified by phenol-chloroform extraction.  Reverse 
transcription took place in the presence (black) or absence (grey) of the reverse transcriptase. (B) 
RNA standard generated without phenol-chloroform extraction.  
 
3.1.1.1.2 Quantification of genomic titers of by qPCR 
Quantification of vector genome copies (gc) within a vector stock does not require 
transduction of cells, but is assessed by qPCR. cDNA, that was reverse transcribed 
from LV RNA, as well as DNA, isolated from AAV stocks, were applied to qPCR. As 
amplification sequence, a sequence which is identical in both vector types is 
required. Therefore, sequences within the transgene, namely egfp or luc, were 
chosen. Using a RNA standard and DNA standard as described in chapter 3.1.1.1 
allowed absolute quantification of genomic titers of LV and AAV vector stocks in 
parallel (Figure 6). 
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Figure 6: Schematic procedure of quantification of genomic titers. DNA was isolated from AAV, 
RNA from LV vector stocks. While the standard for the quantification of AAV titers was generated by 
serial 10-fold dilution of the transfer plasmid, the RNA standard was generated by in vitro transcription. 
The in vitro transcribed RNA fragments were reverse transcribed into cDNA in parallel to the isolated 
RNA from LV stocks. Purified AAV DNA as well as cDNA from LV RNA and the RNA standard were 
applied to qPCR. Genomic titers of lentiviral and AAV vector stocks were determined by comparison 
with the respective standards.  
 
On average, Her2-AAVGFP stocks contained 1.46x1011 gc/ml (± 8.6x1010 gc/ml; N=4), 
whereas genomic titers of Her2-LVGFP stocks were about 10-fold higher showing on 
average 1.35x1012 gc/ml (± 1x1012 gc/ml; N=3) assuming that each lentiviral particle 
contains two RNA genome copies. The same 10-fold difference was detected in 
vector stocks encoding luciferase with 2.25x1011 gc/ml (± 3x1010; N=2) in Her2-
AAVluc stocks and 2.2x1012 gc/ml (± 2x1012; N=4) in Her2-LVluc stocks.  
Table 6: Genomic titers of Her2-LV or Her2-AAV vector stocks 
 Her2-LVGFP 
[gc/ml] 
Her2-AAVGFP 
[gc/ml] 
Her2-LVluc 
[gc/ml] 
Her2-AAVluc 
[gc/ml] 
vector stock 1 7.3x1011 5.9x1010 2.8x1010 2.5x108 
vector stock 2 8.1x1011 1.7x1011 1.6x1012 2.0x108 
vector stock 3 2.5x1012 2.5x1011 2.5x1012  
vector stock 4 7.3x1011 1.0x1011 4.7x1012  
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3.1.1.2 Quantification of physical titers  
Physical titers define the amount of physically intact particles within a vector stock. 
Physical titers include functional and non-functional or empty particles without 
transgene. LV particles were assessed by p24 ELISA which determines the amount 
of p24 protein per vector stock. Assuming that approximately 2000 p24 proteins are 
contained within one LV particle (Wilk et al., 2001), the number of particles within a 
vector stock was calculated. Particles in AAV vector stocks were assessed by capsid 
ELISA. Comparison with a standard vector with known particle concentration allowed 
calculation of particle numbers. On average, Her2-LVGFP vector stocks contained 
7.0x1012 particles/ml (± 6x1012; N=3), accounting for approximately 10-fold more 
particles than Her2-AAVGFP vector stocks which comprise 7.8x1011 particles/ml (± 
6.9x1011; N=4). No significant difference was observed between GFP or luciferase 
transgene containing particles (p=0.1932 (LV), p=0.8752 (AAV)). 2.4x1012 
particles/ml (± 2x1012; N=4) were detected in Her2-LVluc and 8.8x1011 (± 5e11; N=2) 
within Her2-AAVluc vector stocks.  
Table 7: Physical titers of Her2-LV and Her2-AAV vector stocks 
 Her2-LVGFP 
[particles/ml] 
Her2-AAVGFP 
[particles/ml] 
Her2-LVluc 
particles/ml] 
Her2-AAVluc 
[particles/ml]
vector stock 1 3.7x1012 5.3x1011 7.6x1011 1.2x1012 
vector stock 2 3.5x1012 2.8x1011 2.6x1012 5.2x1011 
vector stock 3 1.4x1013 5.1x1011 4.9x1012  
vector stock 4  1.8x1012 1.4x1012  
 
3.1.1.3 Quantification of functional titers  
Genomic and physical titers include functional and non-functional vector particles. 
Vector particles encoding fluorescent transgenes allow the determination of 
functional titers by assessing the fluorescence of transduced cells. 10 to 0.01 µl of 
concentrated Her2-LVGFP and Her2-AAVGFP vector stocks were added to Her2-
positive SK-OV-3 cells. This cell line was selected since it was previously shown to 
be susceptible to Her2-LV and Her2-AAV in vitro as well as in vivo (Münch et al., 
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2011; Münch et al., 2013) and also to form subcutaneous tumors in nude mice 
(Goyeneche et al., 2007). Four days post transduction, GFP expression was 
determined by flow cytometry. On average, the functional titer of Her2-LVGFP was 
7.8x106 tu/ml (N=3). Her2-AAVGFP stocks contained approximately 2.5 more 
functional particles resulting in 2x107 tu/ml (N=4). As expected, the mean 
fluorescence intensity for cells transduced with AAV was in general lower than for LV 
transduced cells (see also Figure 8).   
Table 8: Functional titers of Her2-LV and Her2-AAV vector stocks 
 Her2-LVGFP [tu/ml] Her2-AAVGFP [tu/ml] 
vector stock 1 4.8x106 2.3x107 
vector stock 2 4.7x106 3.5x107 
vector stock 3 1.4x107 9.8x106 
vector stock 4  1.3x107 
 
3.1.1.4 Comparison of functional, genomic and physical titers 
Having quantified genomic, physical and functional titers of Her2-targeted LV and 
AAV vector stocks, these titers were compared. This revealed that physical titers of 
both vector types are higher than functional and genomic titers. Between 2- and 20-
fold more AAV capsids than genomes were detected indicating the presence of 50 to 
95% empty particles in the individual vector preparations. LV vector stocks contained 
approximately 5-fold more physical particles than genomes. Genomic and physical 
titers were about 10-fold higher in LV vector stocks, compared to AAV vector stocks. 
In contrast, the number of tu/ml was increased in AAV vectors approximately 2.5-fold 
(Figure 7 A). Therefore, AAV vector stocks that were analyzed here, consist of about 
10,000-fold more genomes than transducing units, whereas this excess of non-
functional particles in LV vector stocks was even more than 100,000-fold (Figure 7 
B).  
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Figure 7: Comparison of functional, genomic and physical titers of Her2-LVGFP and Her2-
AAVGFP. Functional titers were determined by transduction of SK-OV-3 cells with Her2-LVGFP or Her2-
AAVGFP and subsequent analysis of GFP expressing cells by flow cytometry. Genomic titers were 
assessed by qPCR of reverse transcribed LV RNA and AAV DNA. Particle numbers per ml were 
measured by either p24-ELISA or capsid ELISA. (A) Titers of Her2-LVGFP (N=3) and Her2-AAVGFP 
(N=4) vector stocks. (B) The fold excess of non-functional, but genomes within Her2-LVGFP and Her2-
AAVGFP vector stocks. LV N=3; AAV N=4; mean±SD.  
 
3.1.2 Transduction of Her2+ SK-OV-3 cells with Her2-AAVGFP and Her2-LVGFP in 
vitro 
After quantification of genomic and functional titers, transduction efficiencies of Her2-
LV and Her2-AAV were compared in vitro. SK-OV-3 cells were transduced with either 
Her2-AAVGFP or Her2-LVGFP at identical multiplicity of infection (MOI) or genomic 
particles per cell (GOI). Ninety-six hours post transduction the expression levels of 
GFP were determined by flow cytometry. Transduction of cells by Her2-AAVGFP at a 
MOI of 1 resulted in 7.3% (±1.5%; N=3) GFP+ cells. In contrast, a transduction 
efficiency of 6.9% (± 0.04; N=2) was achieved by transduction of SK-OV-3 cells with 
Her2-LVGFP at a MOI of 0.1 (Figure 9). As described in chapter 3.1.1.3, the mean 
fluorescence intensity of AAVGFP vector transduced cells was lower than that of LVGFP 
transduced cells (Figure 8).  
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Figure 8: Representative flow cytometry plots of SK-OV-3 cells transduced with Her2-LVGFP or 
Her2-AAVGFP. SK-OV-3 cells were transduced at matching MOI (A) or GOI (B). Ninety-six hours post 
transduction; GFP expression was determined by flow cytometry. As it can be seen in the 
untransduced cells, the GFP signal intensity for cells transduced with Her2-AAVGFP was amplified by 
applying higher voltage compared to cells transduced with Her2-LVGFP.   
 
On average, AAV vector stocks contained about 10-fold more functional particles 
within the same amount of genome copies than LV stocks (Figure 7). Therefore, 
normalizing both vector types to the same genome copies led to higher transduction 
efficiency in cells transduced with Her2-AAVGFP. Comparing transduction efficiencies 
of MOI and GOI values, it can be concluded that a MOI of 1 corresponds to 5,000 
GOI of Her2-AAVGFP. On the contrary, transduction of SK-OV-3 cells by Her2-LVGFP 
at a MOI of 1 correlates to 150,000 GOI (Figure 9). These data demonstrate that 
approximately 3 times more genome copies of Her2-LV are required to match the 
number of GFP expressing cells obtained with Her2-AAV. Considering this fact, the 
theoretical amount of functional particles within the number of genome copies used 
for transduction by either Her2-LVGFP or Her2-AAVGFP was determined. This 
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calculation confirmed that about 10-fold more transducing AAV than functional LV 
particles are required to obtain comparable transduction efficiencies. 
 
 
Figure 9: Transduction of SK-OV-3 cells by either Her2-LVGFP or Her2-AAVGFP. SK-OV-3 cells 
were transduced by Her2-LVGFP or Her2-AAVGFP at different MOI or GOI. Four days post transduction 
the cells were analyzed by flow cytometry for GFP expression. LV N=2; AAV N=3; mean±SD. 
 
3.1.3 Biodistribution of Her2-LV and Her2-AAV in a subcutaneous tumor mouse 
model 
3.1.3.1 Particle distribution at early time points after vector administration  
Having analyzed the transduction efficiencies of Her2-LV and Her2-AAV in vitro, the 
particle distribution at early time points after vector administration, when no 
transgene expression has occurred yet, was studied in vivo. Athymic nude mice were 
injected with the same gc number (2x1010) per mouse for both vector types, one 
additional group was implemented receiving 2x1011 gc Her2-LVluc (high vector dose). 
For analysis of the distribution of the vector particles, blood and urine were collected 
and organs (spleen, liver, lung, heart, kidneys) and tumors were isolated 4, 10 and 24 
hours after intravenous vector administration. The distribution of Her2-LVluc in mice 
within the high vector dose group was analyzed after 4 hours. Total RNA was 
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isolated from the homogenized organs of LV injected mice using the RNeasy Mini Kit 
(Qiagen), whereas DNA was isolated using the 96-DNeasy blood and tissue Kit 
(Qiagen) from tissue of AAV injected mice. RNA was transcribed into cDNA. By 
qPCR, LV and AAV genomes within the isolated DNA and cDNA were quantified by 
the use of RNA and DNA standards. In contrast to the determination of AAV and LV 
titers, quantification of vector genomes from organs was performed by using a 
luciferase specific, FAM labeled primer/probe set. Since considerable less luciferase 
DNA was detectable within the organs compared to pure vector stocks, the use of 
SYBR green resulted in unspecific fluorescence signals as confirmed by melting 
curve analysis (data not shown). Using the TaqMan-probe-based assay, no false 
positive signals were measurable.  
In tissue isolated from LV injected mice, the highest genome copy number was found 
in lung at all analyzed time points. In lung and tumor the detectable gc numbers 
slightly increased after 8 hours, compared to the 4 hour time point, but dropped again 
after 24 hours. Twenty-four hours post vector administration, the signals in spleen 
increased, but the gc detectable in heart, kidney and liver decreased below detection 
limit in the three organs and tumor tissue. Comparable signals were found in tumor 
and spleen, however, signals in lung were even increased compared to tumor 
signals. Nevertheless, the differences between the three time points as well as 
between the various organs remained not significant (p>0.05) comparing mice 
injected with the same gc numbers. No LV gc were detectable in blood and urine at 
all analyzed time points. When, 10 times more LV gc were injected, signals were 
approximately 25-fold higher in lung and even 30-fold higher in tumor tissue than in 
mice injected with 2x1010 gc (Figure 10). 
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Figure 10: Biodistribution of vector particles after systemic administration of Her2-LV. Mice 
transplanted with subcutaneous SK-OV-3 tumors were injected with either 2x1010 or 2x1011 genome 
copies of Her2-LVluc. After 4, 8 and 24 hours, the mice were sacrificed and blood and urine collected 
and the indicated organs isolated. The LV genome copies within the organs were determined by 
qPCR using a luciferase-specific primer/probe set. Absolute genomic copies per µg tissue are shown. 
No LV genomes were detectable within blood or urine. N=3; mean±SD. Nd, not detectable. 
 
In mice injected with Her2-AAVluc significantly more vector genome copies were 
detected in spleen than in the other organs. The signals obtained for different time 
points did not significantly differ within the organs except for significant lower gc 
numbers within spleens 24 hours after vector administration (p<0.05). In addition, 
less vector DNA was recovered in liver 24 hours post vector administration, indicating 
de-targeting of the natural liver tropism of AAV-2 wild type. While signals from AAV 
injected mice were mostly comparable with signals from LV injected mice in lung, 
signals from AAV injected mice were 20-300-fold increased in spleen, kidney or liver. 
Within tumor tissue approximately 20-fold more AAV DNA was found compared to LV 
RNA (Figure 10; Figure 11).  
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Figure 11: Biodistribution of vector particles after systemic administration of Her2-AAV. Mice 
transplanted with subcutaneous SK-OV-3 tumors were injected with 2x1010 genome copies of Her2-
AAVluc. After 4, 8 and 24 hours the mice were sacrificed and blood and urine collected and the 
indicated organs isolated. The LV genome copies within the organs were determined by qPCR using a 
luciferase-specific primer probe set. Absolute genome copies per µg tissue are shown. No AAV 
genomes were detectable within urine. N=3; mean±SD.  
 
3.1.3.2 Monitoring the biodistribution of Her2-LV and Her2-AAV by in vivo 
imaging 
After investigating the distribution of Her2-LV and Her2-AAV at early time points after 
vector administration, the transgene expression in mice was analyzed over the period 
of 12 days by in vivo imaging. 2x1010 or 2x1011 gc Her2-LVluc and 2x1010 gc Her2-
AAVluc were injected systemically into nude mice bearing subcutaneous SK-OV-3 
tumors. Luciferase expression in animals was monitored from day 3 to day 12. On 
day 12, the strongest luciferase signals were detectable in tumor tissue of two of the 
three mice that were injected with the high genome copy number (2x1011) of LV. Both 
mice showed some off-target signals in the spleens. In the third mouse of this group, 
the luciferase signals were weaker compared to the rest of the mice and therefore 
they are not visible in Figure 12. Nevertheless, tumor signals in this mouse were 
measurable from day 3 to day 12 and spleen signals starting from day 6. One mouse 
showed a dominant signal with the highest signal intensity on the right side of the 
chest (Figure 12; blue arrow) which was present starting day 6. The source of the 
strong signal could not be identified, since none of the isolated organs or inner skin 
parts showed signals after sacrificing the mouse. No tumor cells were detectable at 
this part of the body. By in vivo imaging no luciferase signals were detectable in mice 
that had received the low genome copy number (2x1010) Her2-LV, which is 
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comparable to the injected AAV genome copy number. Mice injected with Her2-
AAVluc showed tumor specific luciferase expression and in one animal some off-
targeting effects in the chest region (Figure 12).  
 
Figure 12: In vivo imaging of SK-OV-3 tumor bearing nude mice. SK-OV-3 cells were transplanted 
subcutaneously into athymic nude mice (red arrows). After tumor vascularization, 2x1010 or 2x1011 
genome copies of Her2-LVluc or 2x1010 genome copies of Her2-AAVluc were administered systemically. 
Twelve days after vector injection, luciferase expression in mice was analyzed by in vivo imaging. The 
luciferase signal intensity is expressed as photons/second/square centimeter/steradian (p/sec/cm2/sr). 
Blue arrow points out the unidentified signal. 
 
Immediately after in vivo imaging, mice were sacrificed and luciferase signals in the 
isolated tumors and organs measured. Imaging of the organs confirmed results from 
in vivo imaging. Strongest luciferase expression was detected in tumors of mice 
injected with high genome copy number of LV, followed by signals from tumors from 
AAV injected mice. Increasing the sensitivity for luciferase signals revealed that also 
in the spleens of mice injected with the low LV dose luciferase was expressed, but to 
a lower extent than in mice that received the high LV dose. However, in these mice 
no tumor signals were detectable (Figure 13). Although, in AAV injected mice some 
off-targeting effects in the chest region were visible during in vivo imaging, hardly any 
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luciferase signals in heart or lung were measurable. In addition, the highest luciferase 
expression was detected in Her2-positive tumor tissue in mice injected with either 
AAV or the high LV dose. Based on the luciferase expression in athymic nude mice in 
vivo, these results suggest that AAV is more efficient in transduction compared to LV, 
when the same amount of genome copies for both vector types is injected per 
mouse.  
 
Figure 13: Imaging of organs from SK-OV-3 tumor bearing nude mice. SK-OV-3 cells were 
transplanted subcutaneously into athymic nude mice. After tumor vascularization, 2x1010 or 2x1011 
genome copies of Her2-LVluc or 2x1010 genome copies of Her2-AAVluc were administered systemically. 
Twelve days after vector injection, luciferase expression in mice was determined by in vivo imaging. 
Afterwards, the luciferase signal in isolated tissues was analyzed. The luciferase signal intensity is 
expressed as photons/second/square centimeter/steradian (p/sec/cm2/sr). Organs are identified by the 
capital letter below the tissue. T, tumor; H, heart; S, spleen; L, lung; Li, liver; K, kidney.  
 
3.1.4 Serum stability 
To assess, how much the biodistribution of LV or AAV was influenced by sensitivity 
towards serum, the stability of both vector types was tested. For this purpose, serum 
from several athymic nude-Foxn1nu mice that had been used for the biodistribution 
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experiments was collected and pooled. These mice are T-cell deficient but are 
normal in B-cell function (Harlan Laboratories). The serum was pre-incubated with 
either Her2-LVGFP or Her2-AAVGFP in cell culture medium in different concentrations 
at 37°C for 30 min. Then, the serum-vector mixture was added to SK-OV-3 cells. 
Transduction efficiency was determined by flow cytometry 96 hours later and 
normalized to the transduction efficiency of vector without serum addition. 
Furthermore, part of the serum was heat-inactivated prior to incubation with the 
vectors. Transduction efficiency was reduced to 70-80% by addition of 2.5% serum to 
the medium for both vector types. Increasing concentrations of serum reduced the 
transduction efficiencies to approximately 60% for LV as well as for AAV transduced 
cells. Nevertheless, this reduction was not significant. In addition, no significant 
difference between both vector types was observed (Figure 14). Heat-inactivation of 
serum showed comparable results to transduction of cells as in the presence of not 
heat-inactivated serum (data not shown). However, addition of more than 5% serum 
to the medium had a negative effect onto the growth of the cells which might affect 
the transduction of cells. These results demonstrate that the biodistribution of either 
LV or AAV particles is not significantly influenced by neutralization within the used 
mouse model. 
 
Figure 14: Transduction efficiency of either LV or AAV is not significantly impaired by serum of 
athymic nude mice. Her2-LVGFP or Her2-AAVGFP were incubated with the indicated concentrations of 
mouse serum at 37°C for 30 min. Afterwards, the mixtures were added to SK-OV-3. Ninety-six hours 
later, the number of GFP-positive cells was determined by flow cytometry and transduction efficiencies 
were calculated in relation to cells transduced in the absence of serum. N=2; mean±SD.  
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3.2 Targeted gene transfer into human hematopoietic stem cells 
Having demonstrated different aspects of targeted gene transfer by lentiviral and 
AAV vectors the focus of the second part of this thesis is on the selective and stable 
gene transfer into HSCs by LVs.  
Genetic modification of HSCs is commonly achieved by using VSVG-pseudotyped 
lentiviral or retroviral vectors. Due to its broad tropism while maintaining a low risk for 
insertional mutagenesis especially VSVG-LV has shown promising results in several 
clinical studies (Naldini, 2011; Aiuti et al., 2013; Biffi et al., 2013). Nevertheless, 
efficient transduction of HSCs with VSVG-LV requires extensive stimulation of the 
cells and high vector dose whereby several days of ex vivo cultivation is necessary. 
Therefore, we investigated whether targeting a receptor specific for early HSCs may 
represent an alternative transduction approach. 
 
3.2.1 Expression of CD105 on human HSCs 
CD105 is a well-established marker on murine HSCs (Chen et al., 2002; Chen et al., 
2003; Roques et al., 2012) and Pierelli et al. report that CD105 is also present on 
subsets of human HSCs (Pierelli et al., 2000; Pierelli et al., 2001). Therefore, CD105 
surface expression on unstimulated and stimulated human HSCs was analyzed since 
ex vivo expansion and gene modification of HSCs often requires stimulation with 
cytokines, by which the duration of ex vivo culture is prolonged and which might 
facilitate proliferation of different HSC subsets. Human CD34+ cells were purified 
using magnetic beads by positive selection from mobilized peripheral blood. CD105 
surface expression on unstimulated cells or cells stimulated overnight with cytokines 
was analyzed by flow cytometry. Donor dependently, CD105 expression varied 
between 30 – 80% (mean = 60%) in unstimulated cells. The expression levels further 
increased to 95% after overnight stimulation with cytokines (Figure 15). In addition, 
frozen BM CD34+ cells (Lonza) as well as CD34+ isolated from cord blood showed 
similar results (data not shown). This demonstrates that the common endothelial 
marker CD105 is also expressed on human HSCs.  
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Figure 15: Surface expression of CD105 on human CD34+ cells. After purification from G-CSF 
mobilized peripheral blood using CD34 MACS beads, CD34+ cells were analyzed by flow cytometry for 
their CD105 surface expression either immediately or after stimulation for 24 hours with Flt-3 ligand, 
stem cell factor, IL-3, IL-6 and TPO. (A) Representative FACS plots of CD34+/CD105+ cells before and 
after stimulation. (B) Mean±SD of CD105 expression on CD34+ cells from seven individual donors 
(Kays et al., 2015). 
 
3.2.2 Transduction of HSCs using CD105-LV 
3.2.2.1 Transduction of CD34+ cells by CD105-LVGFP 
In the host laboratory, the CD105-targeted vector CD105-LV has been generated 
previously and was shown to selectively transduce CD105+ endothelial cells in mixed 
cultures of CD105+ and CD105- cells (Anliker et al., 2010). In addition, exclusive gene 
transfer into CD105-positive liver sinusoidal endothelial cells in mice reconstituted 
with human liver cells was demonstrated upon systemic administration of CD105-LV 
(Abel et al., 2013).  
Here, the ability of CD105-LV to mediate gene transfer to HSCs was analyzed. 
CD34+ cells were transduced with CD105-LV transferring the marker gene egfp 
(CD105-LVGFP). The vectors were added to the cells either directly after purification 
from mobilized peripheral blood or after overnight stimulation with cytokines. 
Seventy-two hours post transduction the expression levels of GFP were determined 
by flow cytometry. CD105-LVGFP transduced 3 – 5% of unstimulated CD34+ cells and 
up to 20% of stimulated CD34+ cells (Figure 16). All of the GFP+ cells were also 
CD105+ (Figure 16A) demonstrating specificity of the targeting vector.  
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Figure 16: Transduction of unstimulated and stimulated human CD105+/CD34+ cells by CD105-
LVGFP. Unstimulated or stimulated CD34+ cells isolated from G-CSF mobilized peripheral blood were 
transduced by CD105-LVGFP at a multiplicity of infection (MOI) of 1. Seventy-two hours after 
transduction the cells were analyzed by flow cytometry for expression of GFP and CD105. (A) 
Representative FACS plots of GFP+ cells transduced with or without previous stimulation of cells. (B) 
Mean±SD of GFP+ cells of seven independent experiments (Kays et al., 2015).  
 
To further characterize the transduced cells, the cells were checked for the presence 
of additional surface markers known to define early HSCs. Approximately 90% of 
GFP+ cells were also positive for the HSC marker CD133 and about 60% for the HSC 
marker CD90. In addition, the majority (approximately 70%) of transduced cells were 
CD38- (Figure 17), a surface marker that is present on more committed progenitor 
cells. These data demonstrate that CD105 is expressed on a more primitive subset of 
HSCs.  
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Figure 17: Transduction of stimulated human CD34+CD105+ cells by CD105-LVGFP. Stimulated 
CD34+ cells isolated from G-CSF mobilized peripheral blood were transduced by CD105-LVGFP at a 
multiplicity of infection (MOI) of 1. Seventy-two hours after transduction the cells were analyzed by 
flow cytometry for expression of GFP, CD105 and the surface markers CD133, CD90 and CD38. (A) 
FACS plots of one representative experiment. (B) Mean values±SD of four biological replicas (Kays et 
al., 2015). 
 
3.2.2.2 Transduction of CD105 enriched cells by CD105-LVGFP 
After confirming that CD105 is expressed on early HSCs it was analyzed if isolation 
of CD105+ cells from mobilized peripheral blood is as effective as purification of 
CD34+ cells. 
Enrichment of either CD34+ or CD105+ cells from mobilized peripheral blood by 
magnetic activated cell sorting was compared. The CD34+ cell population consisted 
exclusively of cells which showed the typical morphology of HSPCs in subsequent 
cell culture as determined microscopically. In contrast, the cell population that was 
only enriched for CD105+ was also composed of cells that could morphologically not 
be assigned to HSPCs (Figure 18). This indicates that CD105 as exclusive marker for 
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HSC purification from mobilized peripheral blood is not sufficient, but may require 
additional marker for HSC isolation.  
 
Figure 18: Morphology of CD34+ or CD105+ purified cells. CD34+ or CD105+ cells were isolated 
from mobilized peripheral blood by magnetic activated cell sorting. Black arrow heads designate cells 
with HSC morphology. Red arrow indicates cell with atypical HSC morphology.  
 
Therefore, enrichment of CD105+ cells within the CD34+ cell population was 
investigated. CD34+ cells purified from mobilized peripheral blood were either 
subjected to a second round of purification for CD105 using magnetic activated cell 
sorting or CD105high expressing cells were isolated from CD34+ cells by fluorescence 
activated cell sorting. Both methods enriched cells with HSPC morphology, however, 
purification of CD34+CD105+ cells using the MACS Multisort system led only to 
marginal enrichment of CD105+ cells within the CD34+ cell population. In addition, 
these approaches required binding of anti-CD105 antibodies to the cells. Thereby, 
subsequent transduction of cells by CD105-LVGFP was inhibited (Figure 19). As a 
consequence, the approach to further enrich CD105+ cells within the CD34+ cell 
population was not followed up further.  
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Figure 19: Transduction of either CD34+ or CD105+ purified cells. CD34+ or CD105+ cells were 
isolated from mobilized peripheral blood by magnetic activated cell sorting. Stimulated cells were 
transduced by CD105-LVGFP at a multiplicity of infection (MOI) of 1. Seventy-two hours after 
transduction, GFP expression was determined by fluorescence microscopy. 200-fold magnification.  
 
3.2.2.3 Specificity of CD105 dependent transduction 
To confirm the specificity of CD105 dependent transduction of CD34+ cells we pre-
incubated CD105-LVGFP with soluble CD105 protein (sCD105). The extracellular 
domain of CD105 was fused to an Fc-Tag (plasmid kindly provided by Irene 
Schneider and Gundula Braun) and expressed in HEK-293T cells. After HPLC 
purification sCD105 was added in increasing amounts to either CD105-LVGFP or 
VSVG-LVGFP. In addition, also an Fc tagged control protein (sCD30) was added to 
CD105-LVGFP. After pre-incubation of vectors and proteins the vector-protein mixture 
was used for transduction of CD34+ cells isolated from mobilized peripheral blood. 
Pre-incubation of sCD105 with the targeting vector lead to reduced transduction 
efficiency correlating with the amount of protein used. Incubation with 2 µg of 
sCD105 resulted in a decrease of transduction of 95%. In contrast, pre-incubation 
with the control protein sCD30 did not influence the transduction efficiency 
significantly. Also pre-incubation of sCD105 with VSVG-LVGFP did not reduce the 
transduction efficiency (Figure 20). Moreover, binding of magnetic or fluorophore 
labeled anti-CD105 antibodies to CD34-purified cells as described in 3.2.2.2 inhibited 
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transduction of these cells by CD105-LVGFP (Figure 19). These results clearly 
demonstrate that binding of CD105-LV to CD105 on the cell surface is necessary for 
the CD105-LV mediated transduction of CD34+ cells.  
 
 
Figure 20: Transduction of CD34-purified cells by CD105-LVGFP is blocked by soluble CD105. 
The Fc-tagged extracellular part of CD105 (sCD105) or that of CD30 were added to CD105-LVGFP or 
VSVG-LVGFP in the indicated amounts. After 30 min incubation at 37 °C the vector-protein mixtures 
were added to primary human CD34-purified cells at a multiplicity of infection (MOI) of 1 for CD105-
LVGFP and an MOI of 5 for VSVG-LVGFP. Seventy-two hours later, the number of GFP-positive cells 
was determined by flow cytometry and the transduction efficiencies were calculated in relation to those 
obtained in absence of the soluble proteins. N = 2; mean±SD (Kays et al., 2015). 
 
3.2.3 Stable transgene expression in vitro 
To achieve long-lasting gene therapy it is essential that transduction of cells is stable 
and does not influence the self-renewal and differentiation capacity of HSC. 
Therefore, we analyzed the long-term gene expression and the multi-lineage 
potential of CD105-LVGFP transduced cells in vitro and in vivo.  
The colony forming cell assay (CFA) is a validated tool to determine changes in the 
proliferation or differentiation capacity of hematopoietic progenitor cells in vitro. 
Hematopoietic progenitor cells are applied to semi-solid methylcellulose medium 
supplemented with cytokines and growth factors that enable the progenitors to 
proliferate and differentiate into colonies of mature cells. Thus, myeloid multipotential 
progenitors and committed progenitors of the erythroid, monocyte, and granulocyte 
lineages can be enumerated and assessed according to their morphology (Pereira et 
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al., 2007). Therefore, CFA with CD34+ cells transduced either with CD105-LVGFP or 
VSVG-LVGFP was performed. CD34+ were purified from mobilized peripheral blood 
and transduced with either CD105-LVGFP or VSVG-LVGFP. Seventy-two hours post 
transduction the fractions of GFP+ cells were determined by flow cytometry and cells 
applied to the CFA. After 10 days, the numbers of GFP+ colonies and the type of 
colony were determined microscopically. All hematopoietic lineages that can be 
assessed with that assay were detected after colony formation. No significant 
difference was observed in the differentiation of cells derived from mock, VSVG-
LVGFP and CD105-LVGFP transduced cells indicating that the transduction with none 
of the vectors led to an altered differentiation capacity in vitro (Figure 21).  
 
 
Figure 21: Long-term expression of the transgene in CD105-LVGFP transduced human HSCs in 
vitro. A colony forming assay was performed with CD34+ cells purified from G-CSF mobilized 
peripheral blood that were either transduced with CD105-LVGFP (MOI 1), VSVG-LVGFP (MOI 5) or 
medium (mock). After 10 days incubation, the percentages of the indicated hematopoietic lineages 
were determined by fluorescence microscopy. Mean distribution±SD of all colonies is shown in white, 
mean distribution ± SD of GFP+ colonies is shown in grey. Also the percentages of GFP+ colonies in 
relation to the total colonies are indicated. One representative experiment out of three is shown. BFU-
E = burst-forming unit-erythroid; CFU-G = colony-forming unit-granulocyte; CFU-M = colony-forming 
unit-macrophage; CFU-GM = colony-forming unit-granulocyte, macrophage; CFU-GEMM = colony-
forming unit-granulocyte, erythroid, macrophage, megakaryocyte; MOI = multiplicity of infection (Kays 
et al., 2015). 
 
Interestingly, the percentage of GFP+ colonies was higher than the percentage of 
GFP+ cells before CFA. This was especially pronounced for cells transduced with 
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CD105-LVGFP which showed an average increase of 89.7% (N=3; SD ± 14.6) 
compared to 29.3% (N=3; SD ± 13.5) for cells transduced with VSVG-LVGFP (Figure 
22).  
 
Figure 22: GFP expression of CD105-LVGFP or CD105-LVGFP transduced CD34+ cells and their 
derived colonies. CD34+ cells purified from G-CSF mobilized peripheral blood were transduced with 
either CD105-LVGFP (MOI 1) or VSVG-LVGFP (MOI 5). Seventy-two hours after transduction the 
percentage of GFP+ cells was determined by flow cytometry before the cells were applied to a colony 
forming assay. MOI = multiplicity of infection. (A) FACS plots of transduced cells corresponding to the 
colony forming assay shown in Figure 21 (Kays et al., 2015). (B) Percentages of GFP expressing cells 
and colonies. Difference between fractions is indicated. N=3; mean±SD.  
 
These data show that CD105-LVGFP targets a HSC population with extensive 
proliferative and multipotent colony forming capacities.  
 
3.2.4 Stable transduction of CD105-LV transduced cells in repopulated NSG 
mice 
The majority of cells giving raise to colonies in colony forming assays consists of 
more committed progenitor cells whereby not all hematopoietic lineages as well as 
primitive hematopoietic stem cells can be assessed in that short-time assay. Long-
term replicating hematopoietic stem cells are typically identified by repopulation of 
conditioned mice with human cells. The murine hematopoietic system is usually 
destroyed by irradiation followed by transplantation of human HSCs. Then, true 
HSCs that are capable of self-renewal allow restoring of the hematopoietic system 
over months.  
Therefore, it was next investigated in close collaboration with Kerstin B. Kaufmann 
and Manuel Grez (Georg-Speyer-Haus, Frankfurt) whether CD34+ cells transduced 
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with CD105-LVGFP are able to repopulate NSG mice. The expression of GFP within 
transduced cells allows not only the detection of gene modified cells after several 
months but also detailed analysis of the lineage distribution of transduced cells. 
Thereby, it can be also checked if transduction with CD105-LV alters the self-renewal 
as well as differentiation capacity of gene marked cells.  
Fresh CD34+ cells were isolated from human mobilized peripheral blood. After 
overnight stimulation with cytokines cells were transduced with CD105-LV at a MOI 
of 1. The following day, cells were washed with PBS once and injected intravenously 
into sublethally irradiated NOD-scid IL2R-/- mice. Some of the cells were kept for in 
vitro culture to determine the fraction of GFP+ cells by flow cytometry 72 hours post 
transduction. 7-18 weeks after transplantation, blood, spleen and bone marrow cells 
were isolated from mice and analyzed by flow cytometry. Engraftment of human cells 
varied from 13 to 69% in BM and spleen and between 5 and 25% in blood within the 
individual animals (Figure 23A). Human CD45+ cells were further analyzed in regard 
to lineage distribution and GFP expression. As expected from this humanized mouse 
model the majority of human cells were CD19+, but also CD3+ and CD33+ cells were 
detected in BM (Figure 23B) and spleen (Figure 23C). In addition, 10 – 15% of 
human cells in the bone marrow expressed the common HSC marker CD34 (Figure 
23B) indicating self-renewal capacity of the engrafted cells.  
 
Figure 23: Stable engraftment and repopulation of CD105-LVGFP transduced human HSCs in 
vivo. Six weeks old NSG mice (N = 9) were irradiated at 1.8 or 2 Gy. Four hours after conditioning 1.2 
- 1.7x106 CD105-LVGFP transduced human CD34+ cells that were isolated from G-CSF mobilized 
peripheral blood were transplanted intravenously. 7 - 18 weeks post transplantation cells were isolated 
from BM, spleen und blood and analyzed by flow cytometry. (A) Percentage of human CD45+ cells in 
relation to all CD45+ cells. (B) Lineage distribution of human CD45+ cells in BM and (C) spleen (Kays 
et al., 2015). 
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The percentages of GFP+ cells ranged between 5 and 22% in BM, spleen and blood 
(Figure 24A) and reflected the fractions of GFP expressing cells initially transplanted 
into mice (Figure 24B). These data demonstrate that the transgene expression 
remained stable up to 18 weeks and that the transduced cells engrafted efficiently in 
mice. Moreover, cells from all hematopoietic lineages were detected within the GFP+ 
cells from BM (Figure 24C) and spleen (Figure 24D). Unfortunately, the numbers of 
human cells that were recovered from murine blood were too low for further reliable 
lineage analysis. Notable, there were no significant differences in the fractions of 
GFP expressing cells in each hematopoietic lineage in BM (Figure 24C) and spleen 
(Figure 24D) indicating that transduced cells preserved the ability to differentiate into 
the different lineages. This argues for the fact that CD105-LV transduces not 
progenitor cells but indeed HSCs.  
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Figure 24: Stable engraftment and repopulation of CD105-LVGFP transduced human HSCs in 
vivo. Six weeks old NSG mice (N = 9) were irradiated at 1.8 or 2 Gy. Four hours after conditioning 1.2 
- 1.7x106 CD105-LVGFP transduced human CD34+ cells that were isolated from G-CSF mobilized 
peripheral blood were transplanted intravenously. 7 - 18 weeks post transplantation cells were isolated 
from BM, spleen und blood and analyzed by flow cytometry. (A) Percentages of GFP+ cells within the 
engrafted human CD45+ cell population in BM, spleen and blood. (B) GFP expression in human CD34-
purified cells 72 h post-transduction (pre-transplantation) and in engrafted human CD45+ cells (7 - 18 
weeks post-transplantation) in BM and spleen; ns = not significant. Comparable percentages of GFP+ 
cells in each lineage in human CD45+ engrafted (C) BM and (D) spleen cells; differences not 
significant according to 1-way ANOVA analysis: p=0.2752 (BM), p=0.1254 (spleen). BM = bone 
marrow; h = human (Kays et al., 2015). 
 
3.2.5 Competitive repopulation of CD105-LV or VSVG-LV transduced HSCs in 
NSG mice 
Next, the repopulation capacities of CD34+ cells transduced with either CD105-LV or 
VSVG-LV were compared in a competitive setting in vitro and in vivo. CD105 or 
VSVG pseudotyped vector particles transferring either GFP or BFP were generated, 
resulting in four different vector types: CD105-LVGFP, CD105-LVBFP, VSVG-LVGFP and 
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VSVG-LVBFP. By having both pseudotypes with both transgenes one can exclude that 
expression of one of the transgene causes more cell stress than the other. Then, 
CD34+ cells were transduced with one of the vectors without pre-stimulation but in 
the presence of cytokines aiming to obtain matching transduction efficiencies of 
around 5% transduced cells. On the next day, CD105-LVGFP and VSVG-LVBFP as well 
as CD105-LVBFP and VSVG-LVGFP transduced cells were mixed in a 1:1 ratio 
resulting in two different cell pools each consisting of GFP+, BFP+ and untransduced 
cell populations. From these cell pools aliquots were taken for a prolonged in vitro 
culture, whereas the majority of cells were transplanted into sublethally irradiated 
NOD-scid IL2R-/- mice (0.5 to 1.0x106 mobilized CD34+ cells per mouse, N = 7). 48 h 
post transduction the marker gene expression was analyzed by flow cytometry 
(Figure 25).   
 
 
Figure 25: Experimental setting of competitive repopulation experiment. CD34+ cells were 
isolated from mobilized peripheral blood and transduced with either CD105-LVBFP or VSVG-LVGFP (or 
vice versa) in the presence of cytokines. On the next day, cells were pooled in a 1:1 ratio and either 
cultured further in vitro or transplanted into sublethally irradiated NSG mice. Levels of marker gene 
expression in cells of the prolonged in vitro culture were determined by flow cytometry. Expression of 
marker genes as well as various cells surface markers from cells isolated from engrafted mice were 
analyzed by flow cytometry 8 weeks post transplantation.   
 
Corresponding with the anticipated transduction efficiency of 5% we detected for both 
vectors approximately 2.5 – 3% of marker positive cells (Figure 26 A). In both 
combinations a slightly higher percentage of gene marking was observed for cells 
transduced by VSVG-LV as indicated by ratios of 1.3 and 1.1 (%VSVG-LV 
transduced cells/%CD105-LV transduced cells). From day 2 to day 10 every other 
day samples from the pooled cell populations were analyzed for marker gene 
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expression by flow cytometry. GFP/BFP expression mediated by CD105-LV was 
maintained to a similar percentage throughout the prolonged cell culture, whereas a 
loss of 60% of marker gene positive cells was detected for VSVG-LV transduced 
cells (Figure 26B). This demonstrates that CD105-LV provides transduction of cells 
that are maintained and/or proliferate throughout prolonged cell culture. 
 
Figure 26: Competitive repopulating capacity of CD105-LV vs. VSVG-LV transduced HSCs in 
vitro. CD34+ cells purified from G-CSF mobilized peripheral blood were transduced either with CD105-
LVGFP, CD105-LVBFP, VSVG-LVGFP or VSVG-LVBFP. The next day VSVG-LVBFP and CD105-LVGFP and 
vice versa transduced cells were mixed to equal parts. (A) Representative FACS plot after pooling of 
the cells 48 h post transduction. (B) In vitro monitoring of transgene expression in triplicates of both 
pseudotype and transgene combinations normalized to the percentage of transduced cells 48 h post 
transduction; mean±SD; differences are significant on day 6 (p=0.004), day 8 (p=0.0024) and day 10 
(p=0.0004). GFP = green fluorescent protein; BFP = blue fluorescent protein (Kays et al., 2015). 
 
Eight weeks after transplantation bone marrow and spleen cells were isolated from 
the humanized mice. All animals showed moderate to high levels of human cell 
engraftment (%humanCD45+/%totalCD45+: 41.1±11.8% (BM); 30.0±6.6% (spleen)) 
Figure 27A). Further analysis revealed that similar to the repopulation experiment 
described in 3.2.4 the majority of human CD45+ cells were CD19+ (Figure 27B, C). 
Cells transduced with CD105-LV showed transgene expression in all hematopoietic 
lineages without significant differences (mean values of 2-4%) correlating or even 
exceeding the initial percentage of marker positive cells that were transplanted. In 
contrast, cells transduced with VSVG-LV showed less than 2% of marker gene 
expression cells meaning a loss compared to the initial input. The only exception was 
CD33+ splenocytes maintaining the fraction of marker gene positive cells (Figure 27D 
- F).  
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Figure 27: Engraftment and lineage distribution of human cells in NSG mice in competitive 
repopulation experiments. CD34+ cells purified from G-CSF mobilized peripheral blood were 
transduced either with CD105-LVGFP, CD105-LVBFP, VSVG-LVGFP or VSVG-LVBFP. The next day 
VSVG-LVBFP and CD105-LVGFP and vice versa transduced cells were mixed to equal parts. 0.5 - 0.6 x 
106 cells/mouse were injected intravenously. Eight weeks post transplantation cells were isolated from 
BM and spleen and analyzed by flow cytometry for human and murine CD45 expression as well as for 
expression of human lineage markers and transgene expression (GFP+ or BFP+ = marker+) in the 
hCD45+ population; filled circles = CD105-LV; open circles = VSVG-LV. (A) Engraftment of human 
cells in BM and spleen. Lineage distribution of human CD45+ engrafted BM (B) and spleen (C) cells. 
(D) Engraftment of CD105-LV transduced cells is significantly enhanced in spleen (p=0.009) 
compared to VSVG-LV transduced cells; no significant differences in the distribution of  marker-
positive cells in each lineage of human CD45+ engrafted BM (D) and spleen (F) cells (one-way 
ANOVA analysis: p=0.3326 (BM, CD105-LV), 0.5484 (BM, VSVG-LV), p=0.0816 (spleen, CD105-LV), 
p=0.0871 (spleen, VSVG-LV)). GFP = green fluorescent protein; BFP = blue fluorescent protein; BM = 
bone marrow; h = human (Kays et al., 2015). 
 
Comparing the ratios of gene-marking retrieved in vivo (post-transplantation) to 
marker positive cells pre-transplantation resulted in ratios of approximately 1 in BM 
and spleen upon transduction with CD105-LV while ratios for VSVG-LV were 
significantly lower (Figure 28A). To further demonstrate the difference in performance 
between both vector types the ratio of CD105-LV to VSVG-LV transduced cells within 
each individual animal was determined and set in proportion to the corresponding 
input cell population. Thus, values above 1 indicate a repopulation advantage of cells 
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transduced by CD105-LV. This revealed in BM a 29-fold and in spleen a 9-fold 
superior engraftment of cells transduced by CD105-LV compared to cells transduced 
with VSVG-LV demonstrating that CD105-LV facilitates transduction of unstimulated 
CD34+ HSCs that are able to repopulate NSG mice at sustained levels (Figure 28B). 
These results suggest CD34+/CD105+ cells have a high repopulating capacity in NSG 
mice and confirm that CD105 can serve as a phenotypic marker of early human 
HSCs. 
 
Figure 28: Competitive repopulating capacity of CD105-LV vs. VSVG-LV transduced HSCs in 
vivo. (A) Cells transduced with CD105-LV showed stable expression of the transgene reflected by the 
ratio of gene-marked cells at final analysis compared to the initial transduction efficiency. The 
respective ratios for VSVG-LV were significantly lower as analyzed with the Wilcoxon matched-pairs 
signed rank test; * = p<0.05 [p=0.0313 (BM); p=0.0156 (spleen)]. (B) The relative ratio was obtained 
by dividing the ratio of the different pseudotype transduced cells (CD105-LV/VSVG-LV) within one 
individual animal (in vivo) by the corresponding ratio obtained 48 h post transduction (in vitro). Values 
above 1 indicate superior performance of CD105-LV compared to VSVG-LV. Mean fold change in BM 
and spleen are specified. Significance according to Wilcoxon matched-pairs signed rank test; * = 
p<0.05 [p=0.0313 (BM); p=0.0156 (spleen)] is shown. BM = bone marrow; tx = transplantation; h = 
human (Kays et al., 2015). 
 
3.2.6 Vector mediated toxicity on CD34+ cells 
Lentiviral transduction might lead to some cell stress or toxicity. To address this issue 
vector mediated cell toxicity was investigated. CD34+ cells were transduced with 
either CD105-LVGFP or VSVG-LVGFP aiming to obtain the same transduction 
efficiencies with both vectors. Forty-eight hours after transduction we analyzed the 
fractions of early apoptotic and late apoptotic/necrotic cells by annexin V/PI staining. 
Annexin V binds to phosphatidylserine that translocates to the extracellular cell 
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membrane upon apoptosis induction. Cells undergoing early apoptosis are only 
stained with annexin V, whereas late apoptotic or necrotic cells are stained for both 
annexin V and PI. Cells transduced with CD105-LV showed significantly more 
apoptotic cells (mean: 11.2 ± 1.9%) than the mock transduced cells (mean: 5.3 ± 
1.4%) (Figure 29). However, more than 80% of the CD105-LV transduced apoptotic 
cells were in the early apoptotic phase and some of these might recover and not 
enter the late apoptotic status. No significant differences were detected between 
VSVG-LV and mock transduced cells as well as between CD105-LV and VSVG-LV 
transduced cells. Therefore, it can be excluded that the superior engraftment 
potential of CD105-LV transduced cells that was observed in chapter 3.2.6 was due 
to a more toxic effect of VSVG-LV on the cells, but rather that CD105-LV transduces 
a more primitive subset of CD34+ cells. 
 
Figure 29: Apoptosis induction upon transduction. CD34+ cells purified from G-CSF mobilized 
peripheral blood were transduced either with CD105-LVGFP or VSVG-LVGFP resulting in similar 
transduction efficiencies of 11-18%. After 48 h the fractions of early and late apoptotic/necrotic cells 
were determined by annexin V/PI staining. Early and late apoptotic cells as well as necrotic cells were 
included into analysis of vector mediated toxicity. According to one-way ANOVA no significant 
differences were observed between both mock and VSVG-LV transduced cells and between CD105-
LV and VSVG-LV transduced cells. CD105-LV transduced cells showed significantly more apoptotic 
cells (p<0.05) compared to the mock control (Kays et al., 2015). 
  
  DISCUSSION 
74 
 
4. DISCUSSION 
4.1 Side by side comparison of lentiviral and AAV vectors 
The comparison between two different vector types for their gene transfer activities is 
not at all trivial, since lentiviral and AAV vector constructs differ in many aspects such 
as their structural organization, mode of gene expression and entry receptors used. 
Additionally, LVs integrate the transgene into the host cell’s genome allowing stable 
transgene expression, while AAV vectors are present in the cell episomally. 
Therefore, the normalization of lentiviral and AAV vector particles for a convincing 
side by side comparison is critical. Normalization can be based on physical, genomic 
or functional titers. Genomic titers include vector particles containing vector 
genomes, but comprise also non-functional particles that contain genetic information, 
but are not able to transduce target cells or lead to transgene expression. 
Quantification of genomic titers is performed by quantitative real-time PCR. While the 
DNA from AAV vectors can be isolated and used for qPCR directly, LV RNA has to 
be reverse transcribed into cDNA for qPCR first. Physical titers can be determined by 
ELISA and include empty and non-functional particles. Functional titers are 
determined by transduction of cells expressing the entry receptor of the respective 
vector. Thus, comparing different vectors that do not use the identical entry receptor 
bias the quantification of functional titers. While VSVG-pseudotyped LVs can 
transduce a variety of cells, since the VSV receptor is expressed on most of the 
mammalian cells, the transduction ability of recombinant AAV vectors depends on the 
natural tropism of the AAV serotype used for capsid formation. Therefore, 
comparison of different AAV vector serotypes is already challenging. Comparing 
different vector types, such as lentiviral and AAV vectors, is even more difficult. 
Nevertheless, several studies previously compared the performance of lentiviral and 
AAV vectors in various gene transfer approaches in terms of efficacy, safety and 
biodistribution.  
One of these studies describes the in vitro identification of the best vector for the 
transduction of various lung cancer cells for a potential anti-cancer treatment. Five 
recombinant AAV vectors generated from the AAV2 backbone combined with the 
capsid proteins of the AAV1, AAV4, AAV5 or AAV8 serotypes were compared to 
VSVG-LV and normalized to identical MOIs. The AAV vectors transduced 6 out of 11 
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cell lines, while VSVG-LV was able to transduce 10 different cell lines efficiently at 
low vector doses. This was attributed to the natural tropism of the AAV serotypes. In 
addition, transduction with AAV vectors required the use of higher vector doses. The 
vector doses were adjusted to functional particles, however, the functional titers for 
both vector types were determined by the transduction of different cell lines (Chen et 
al., 2013). Thereby, normalization based on functional titers is precarious. Altering 
the natural tropism of vectors circumvents the titer variability based on different cell 
tropism. This can be achieved by using receptor-targeted vectors that bind to the 
same cell entry receptor. Quantification of functional titers of lentiviral and AAV 
vectors by transduction of the same cell line was demonstrated in this thesis.  
In another study, aiming at identifying the best vector for gene therapy of hemophilia 
B, Vandendriessche et al. generated AAV8, AAV9 and lentiviral vectors transferring 
factor IX (FIX) from the same hepatocyte-specific expression cassette. Normalized to 
genome copies, lentiviral gene transfer into FIX-deficient mice resulted in stable 
transgene expression at low therapeutic levels, while the use of AAV serotypes 8 and 
9 led to supraphysiological FIX expression levels. LV-based FIX expression did 
evoke a short-term proinflammatory cytokine induction, while this was not observed 
in AAV vector injected mice. However, AAV9 vector resulted in unexpectedly high 
transgene expression in the heart, emphasizing the adequate choice of capsid 
serotype of AAV vectors (Vandendriessche et al., 2007). By the use of receptor-
targeted vectors using the same entry receptor, the natural tropism of vectors is 
altered and gene transfer is restricted to specific cell types. In vivo application is 
therefore not biased by different cell tropism of vectors. This allows the comparison of 
different vector types in terms of distribution, transgene expression or potential 
immune responses.   
So far, studies comparing lentiviral and AAV vectors have focused mainly on the 
comparison of the performance of lentiviral and AAV vectors in specific gene 
therapeutic applications (Harvey et al., 2002; Ahmed et al., 2004; Vandendriessche 
et al., 2007; Vande Velde et al., 2011; Wang et al., 2012; Chen et al., 2013; Joyeux 
et al., 2014). All of the LVs included in these studies were pseudotyped with VSVG, 
whereas binding of the AAV vectors to cells was achieved by the natural tropism of 
the capsid AAV serotypes. In this thesis, receptor-targeted lentiviral and AAV vectors 
presenting the same targeting ligand, namely the DARPin 9.29, on the particle 
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surface, were compared. Her2-LV and Her2-AAV use the same entry receptor, 
Her2/neu, for selective transduction of cells, allowing for the first time a side by side 
comparison of lentiviral and AAV vectors. Functional titers were determined by 
transduction of Her2/neu expressing SK-OV-3 cells (3.1.1.3). Genomic titers of Her2-
LV and Her2-AAV were quantified by qPCR using the same amplification target 
(3.1.1.1.2). This minimizes the variability in quantification of titers and thereby allows 
a more reliable normalization of Her2-LV and Her2-AAV. Since transduction of both 
vectors is mediated by binding of the DARPin 9.29 to the cell entry receptor 
Her2/neu, the distribution of both vector types can be analyzed in vivo independently 
from their natural receptor usage, that have influenced comparative studies so far.    
  
4.2 Side by side comparison of Her2-LV and Her2-AAV 
Lentiviral and AAV vectors are the preferred tools in current gene therapeutic 
approaches. Depending on the desired application, one system may be preferable 
over the other. In this thesis, receptor-targeted lentiviral and AAVs using the same 
receptor for cell entry were compared side by side for the first time. Lentiviral and 
AAV vectors expressing the same targeting ligand on the particle surface, namely the 
DARPin 9.29, which mediates gene delivery into Her2/neu-positive cells, had been 
generated and characterized before (Münch et al., 2011; Münch et al., 2013). In this 
thesis, genomic, physical and functional titers of several Her2-LV and Her2-AAV 
vector stocks were analyzed and both vector types compared in vitro and in vivo.  
The quantification of genomic titers was based on a qPCR method using an 
amplification target sequence within the transgene to allow titer determination of both 
Her2-LV and Her2-AAV within one single qPCR run. On average, Her2-AAVGFP 
vector stocks contained 1.46x1011 gc/ml. Hence, the genomic titers are similar to that 
of AAV2 wild-type vectors and correspond to those of previous Her2-AAV vector 
preparations (Münch, 2013). The average genomic titer of Her2-LVGFP vector stocks 
was 1.35x1012 gc/ml, thus, approximately 10-fold more genomes were present than in 
Her2-AAVGFP vector stocks. However, an amplification target within the transgene 
was selected for the qPCR, so, it cannot be excluded that contaminating mRNA 
transcripts from the producer cells had been packaged into the vector particles or co-
concentrated, resulting in an overestimation of the true genomic titers of Her2-LV 
  DISCUSSION 
77 
 
vector stocks. One can circumvent that by selecting an amplification target within the 
LTRs (Geraerts et al., 2006). Since the LTR sequences are not present within the 
AAV vector genome, it was decided against this option. As an alternative 
amplification sequence during qPCR, sequences within the promoter gene are 
conceivable, since, no mRNA transcripts would influence the quantification of 
genomic titers. While the genomic titers of Her2-LV vector stocks might have been 
overestimated, it is very unlikely that mRNA transcripts or contaminating plasmid 
DNA from the AAV vector production contributed to the genomic titers of Her2-AAV 
vector stocks. The purification of AAV vector stocks included benzonase treatment 
and density gradient centrifugation, while the produced LVs were purified only by 
centrifugation through a sucrose cushion. Additionally, RNase digestion was 
implemented during DNA isolation of AAV genomes. Potential contaminating plasmid 
DNA was removed from LV particles by DNase I digest. However, total RNA was 
purified from LV vector stocks, which might have led to the co-isolation of lentiviral 
RNA and mRNA transcripts.  
Physical particles of Her2-LV and Her2-AAV vector stocks were determined by 
ELISA. Based on the assumption that one lentiviral particle contains approximately 
2000 p24 proteins (Wilk et al., 2001), the number of physical particles within Her2-
LVGFP vector stocks was calculated and accounted on average for 7.0x1012 
particles/ml. This is consistent with previous data on stocks of receptor-targeted LVs 
(Anliker et al., 2010). Her2-AAVGFP vector stocks contained 7.8x1011 particles/ml 
which corresponds to previously obtained particle numbers (Münch et al., 2013). 
The particle numbers of both Her2-LV and Her2-AAV exceeded the number of 
genomes (Figure 7A). Comparing physical particles to numbers of genomes revealed 
that both LV and AAV vector stocks comprised approximately 80% empty particles. 
The ratios of total to genome containing particles within Her2-AAV vector stocks were 
similar to previous observations (Münch et al., 2013). In addition, a ratio equal or 
below 50 had been determined to be wild-type AAV vector phenotype (Grimm et al., 
1999). With a ratio of approximately 5, Her2-AAVGFP was clearly within the expected 
range. It was also previously shown that physical particle numbers of VSVG-LV 
usually exceed the numbers of genomes (Geraerts et al., 2006). 
For the quantification of functional titers, SK-OV-3 cells were transduced with serial 
dilutions of Her2-LVGFP and Her2-AAVGFP and the transduction efficiencies were 
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determined by flow cytometry. On average, the functional titer of Her2-LVGFP 
accounted for 7.8x106 tu/ml, while Her2-AAVGFP vector stocks contained about 2x107 
tu/ml. Comparing the numbers of functional particles and genomes revealed that 
genomic titers exceeded the functional particles of Her2-AAV about 10,000-fold and 
that of Her2-LV by about 100,000-fold (Figure 7B). While it cannot be excluded that 
the true genome copies within LV vector stocks were overestimated, it was 
demonstrated by several groups that RNA-based titration methods led to 10-10,000-
fold more genomes than functional VSVG-LV particles (Scherr et al., 2001; Sastry et 
al., 2002; Lizée et al., 2003; Geraerts et al., 2006). These data are in line with the 
results obtained here, considering that the yield of functional particles of receptor-
targeted LVs is about 35-fold decreased compared to VSVG-LVs (Anliker et al., 
2010).  
The amount of functional particles within the Her2-AAV vector stocks was about 10-
fold higher than in lentiviral vector stocks, but Her2-LV vector stocks contained about 
10-fold more genomes (Figure 7A). Thus, Her2-LV compensates for the lower 
amount of functional particles. However, normalizing vectors to the same genome 
copy number resulted in higher transduction efficiencies in AAV-transduced cells, 
since more functional particles were present in the transduction mix. In contrast, 
normalizing to functional particles required an approximately 10-fold higher MOI of 
Her2-AAV than Her2-LV (Figure 9). This was attributed to the ability of LVs to 
integrate their transgenes into the host’s genome, while AAV vectors remain 
episomally in the target cells. As a result, AAV vectors are diluted out and finally lost 
during proliferation of the cells.  
SK-OV-3 cells transduced with Her2-LVGPF resulted in higher mean fluorescence 
intensity (MFI) of GFP expression than in cells transduced with Her2-AAVGFP (Figure 
8). This indicates that the protein expression per cell is higher in LV transduced cells 
compared to AAV transduced cells. This was also previously observed in a study 
comparing VSVG-LV, a non-integrating lentiviral vector (NILV) and AAV vector in 
terms of transgene expression. The three vectors contained the identical expression 
cassette consisting of the SFFV promoter, egfp and the wPRE sequence. The MFIs 
of the GFP expression of episomal NILV and AAV vectors were lower than that of 
VSVG-LV. It was further determined that the expression per copy of DNA delivered 
by VSVG-LV was 3-5 fold higher compared to DILV and AAV vector. Apolonia 
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suggested that transgene expression mediated by VSVG-LV is higher than that of 
episomally present NILV, because LVs tend to integrate their genome into 
transcriptionally active genome sites (Schröder et al., 2002; Mitchell et al., 2004). 
Another explanation could be that episomally present genomic information is not as 
easily accessed by the transcription machinery than that of the integrated LV 
(Apolonia, 2009).    
As Her2/neu is overexpressed in several tumor cells, a subcutaneous tumor mouse 
model was used to analyze the distribution of the Her2-targeted vectors in vivo. The 
same amount of genome copies of Her2-LVluc and Her2-AAVluc were administered via 
the tail vein. Shortly after vector administration (4, 8 and 24 hours) LV RNA, 
respectively, AAV vector DNA was isolated from different tissues. In mice injected 
with Her2-LV, RNA was detectable in spleen up to 24 hours post vector 
administration. In all other organs, the LV RNA levels decreased 4 hours after vector 
injection and were not detectable anymore 24 hours post vector administration 
(Figure 10). This was confirmed by the results obtained from in vivo imaging that 
showed only minor luciferase signals in the spleens of mice injected with Her2-LV 
(Figure 12; Figure 13). By isolation of RNA from tissue followed by transgene specific 
qPCR, it was not possible to distinguish between RNA derived from LV particles and 
luc mRNA produced by transcription of integrated LV genomes. However, the data 
obtained here are consistent with observations demonstrating that the amount of 
RNA detectable in organs decreased during the first 24 hours after VSVG-LV 
injection in mice. The RNA levels then increased 72 hours after vector administration 
indicating vector mediated transcription (Brown et al., 2007). Others showed that 
DNA integration of HIV-based vectors is detectable earliest 12 hours post 
transduction (p.t.) and reaches a plateau around 48 hours p.t. (Butler et al., 2001; 
van Maele et al., 2003).  
The fact that no luciferase expression was detected 12 days after LV administration 
in vivo was attributed to the lower amount of functional particles injected into mice 
compared to Her2-AAV. Corresponding to the data obtained in vitro, a 10-fold higher 
Her2-LV vector dose led to detectable luciferase expression in the tumor and some 
off-target signals in the spleen (Figure 12; Figure 13). This amount of receptor-
targeted LV corresponds to vector doses that were administered systemically before 
(Münch et al., 2011; Abel et al., 2013).  
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Analysis of AAV DNA isolated from organs shortly after vector administration 
revealed that during the first 24 hours, the distribution of Her2-AAV did not 
significantly differ between the organs except for a reduced spleen signal 24 hours 
post vector injection (Figure 11). While the AAV vector DNA was not predominant in 
tumor tissue 24 hours post vector administration, the highest luciferase expression 
signals were detected in tumors by in vivo imaging (Figure 12; Figure 13). Therefore, 
it can be concluded that vector particle accumulation in tumor tissue by Her2-AAV 
does not occur within the first 24 hours after vector administration. Organs were not 
perfused prior to isolation of DNA to remove remaining blood cells. It is therefore 
possible that Her2-AAV was not present in tissue but was rather still present in the 
blood of the organs. Perfusion of the organs prior to DNA isolation should then result 
in lower vector amounts within the tissues. Additionally, time points later than 24 
hours post vector administration are required to confirm that Her2-AAV circulates 
stably for a prolonged time period in vivo compared to Her2-LV.  
Based on the ratios of functional to genomic titers as well as luciferase expression in 
athymic nude mice in vivo, these results suggest that AAV is more efficient in 
transduction compared to LV, when the same amount of genome copies for both 
vector types is injected per mouse.  
 
4.3 Hematopoietic stem cell-targeted lentiviral vectors 
Today’s standard procedure for gene delivery into HSCs is ex vivo transduction using 
VSVG-pseudotyped LVs. Since quiescent HSCs lack the VSV entry receptor LDL-R 
(Amirache et al., 2014), efficient transduction of CD34+ cells by VSVG-LV requires 
cytokine stimulation of the cells. This method has been successful in clinical 
applications (Cartier et al., 2009; Aiuti et al., 2013; Biffi et al., 2013). While 
unstimulated cells show higher long-term engraftment potential, stimulation facilitates 
cell cycle transit from quiescent cells resulting in impaired long-term repopulation 
capacities (Kittler et al., 1997; Glimm et al., 2000). Therefore, several additional LV-
based approaches for efficient transduction of primitive HSCs have been 
investigated.  
This thesis investigates the use of receptor-targeted LVs. For the rational design of 
LVs targeted to primitive HSCs, receptors expressed on long-term repopulating cells 
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have to be identified. Pierelli et al. showed that human CD34+CD105+ sorted cells 
represent an immature cell population containing primitive hematopoietic precursor 
cells that are significantly more enriched in long-term culture-initiating cells (LTC-IC) 
compared to CD34+CD105- cells (Pierelli et al., 2000). However, the time period for 
this in vitro analysis was limited to 5 weeks and in vivo experiments that allow an 
assessment of the long-term repopulation capacity of cells were missing. By 
oligonucleotide microarray analysis of the mouse BM side-population (SP) enriched 
in HSC activity, mouse CD105 was identified as functional marker of long-term 
repopulating murine HSCs. These findings were confirmed by a competitive 
repopulation experiment. Transplantation of SP CD105+ cells resulted in an increase 
of donor cells whereas a decreased reconstitution contribution of SP CD105- donor 
cells was observed (Chen et al., 2002).  
CD105 is a component of the TGF- receptor complex (St-Jacques et al., 1994; 
Warrington et al., 2005). The role of CD105 in maintaining the primitive state of HSCs 
is still not fully understood. It is suggested that CD105 as well as CD34 are positively 
regulated by TGF-1 in hematopoietic cells and that TGF-1 is the main soluble 
factor that inhibits the cell cycle progression of primitive precursor cells, thereby 
preserving their proliferative capacity (Hatzfeld et al., 1991; Pierelli et al., 2001). In 
this thesis, the long-term repopulating capacity of human CD105+ cells was evaluated 
using receptor-targeted LV.  
CD34-purified cells were transduced with CD105-LVGFP and then engrafted into NSG 
mice. After 7-18 weeks, similar fractions of gene marked human cells were detected 
in blood, BM and spleen compared to the percentages of GFP+ cells that were initially 
transplanted (Figure 24). This demonstrates the long-term stability of transgene 
expression and efficient engraftment of transduced cells into mice. Interestingly, 
similar percentages of gene marked cells in the analyzed lineages were obtained 
suggesting that multipotent HSCs, rather than more differentiated and hence lineage-
restricted progenitors, had been transduced. This is in accordance with results found 
in vitro by CFA (Figure 21). The specificity of CD105-LV was proven by blocking the 
transduction of CD34+ cells through incubation of CD105-LV with soluble CD105 
protein (Figure 20). In addition, off-target transduction was not observed in mixed 
cultures of CD105+ endothelial cells and CD105- peripheral blood mononuclear cells, 
or after systemic vector administration in mice transplanted with human CD105+ cells 
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(Anliker et al., 2010; Abel et al., 2013). Therefore, it can be concluded that the gene 
marked cells in mice or colonies must have been derived from CD105+ HSCs. 
Additionally, the long-term repopulation potential of either CD105-LV or VSVG-LV 
transduced cells was compared in vivo. VSVG-LV and CD105-LV were labeled with 
different fluorescent reporter genes and CD34+ cells were transduced with one of the 
vector types. This allowed transplantation and tracking of either CD105-LV or VSVG-
LV transduced cells within the same animal. The fractions of CD105-LV transduced 
cells remained stable or even increased in vitro as well as in vivo whereas the 
percentage of VSVG-LV transduced cells decreased over time (Figure 26A; Figure 
28A). This resulted in a 29-fold superior engraftment of CD105-LV transduced cells in 
BM and 9-fold superior engraftment in spleen than cells transduced with VSVG-LV 
(Figure 28B) demonstrating that CD105-LV is capable of transducing long-term 
repopulating cells. 
Certainly, the transduction conditions that were used for the competition assay favor 
CD105-LV, since cells were transduced with a low vector dose to gain comparable 
transduction efficiencies. The high amount of VSVG-LV that is usually used for 
transduction of CD34+ cells in clinical settings most likely facilitates the transduction 
of the relatively small HSC population capable of self-renewal. In these experiments, 
VSVG-LV probably transduced the vast excess of multilineage progenitor cells with 
short-term engraftment properties as well as more differentiated lineage-restricted 
progenitors with low or no engraftment potential. In addition, cells were transduced 
without pre-stimulation. While quiescent CD34+ cells lack the VSV entry receptor 
LDL-R, CD105-LV transduced unstimulated CD34+ cells. This resulted in sustained 
transduction levels in repopulated NSG mice. These data suggest that CD34+CD105+ 
cells represent an early stem cell population with high repopulating capacity and 
confirm that CD105 is a marker on primitive human HSCs.  
Further evidence for this could be obtained by mixing limiting dilutions of either 
CD105-LV or VSVG-LV transduced cells with non-gene marked cells and transplant 
these cells into mice. The lowest number of gene-marked cells necessary for 
successful contribution for reconstitution of a human hematopoietic system could 
therefore be determined. Then, the frequency of long-term repopulating cells within 
the gene marked cell population could be calculated. According to the results 
presented in this thesis, one can assume that the frequency of long-term 
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repopulating HSCs is higher in the CD105-LV transduced cell population than in the 
VSVG-LV gene marked cell population. 
As demonstrated in this thesis, CD105-LV is able to transduce unstimulated CD34+ 
cells more efficiently than VSVG-LV. Also other approaches have been investigated 
to improve transduction of quiescent cells. Verhoeyen et al. generated VSVG-
pseudotyped LVs displaying “early-acting-cytokines”, namely thrombopoietin (TPO) 
and stem cell factor (SCF). CD34+ cells were not pre-stimulated by adding cytokines 
to the medium, but cells were only stimulated during vector particle entry. Using this 
transient stimulation, the transduction efficiency was enhanced while maintaining the 
stem cell capabilities of the transduced cells. This resulted in selective transduction of 
long-term repopulating cells (Verhoeyen et al., 2005). This cytokine displaying vector 
was improved by replacing the VSVG with RDTR, a chimeric envelope protein 
consisting of the extracellular and transmembrane domains of the feline leukemia 
virus RD114 and the cytoplasmic tail of the murine leukemia virus amphotropic 
envelope (MLV-A) (Di Nunzio et al., 2007). This newly generated vector 
RDTR/SCFHA-LV was able to obtain higher transduction rates of CD34+ cells in 
unfractioned blood of patients suffering from Fanconia anemia, compared to RDTR-
LV, VSVG/SCFHA-LV or VSVG-LV. In addition, the vector preferentially transduced 
CD34+ cells in mice reconstituted with human HSCs after intrafemural vector 
administration (Frecha et al., 2012).  
Another vector that was rationally generated to transduce primitive and unstimulated 
HSCs is the CD133-targeted LV. CD34 and CD133 expression on HSCs correlates 
well, but HSCs include a subpopulation of CD34-CD133+ cells that can be converted 
to CD34+CD133+ cells, indicating that CD34-CD133+ cells represent a more primitive 
HSC population, and that CD133 is a marker for long-term repopulating HSCs 
(Gallacher et al., 2000). Brendel et al. produced CD133-targeted LV (CD133-LV) 
using vectors pseudotyped with the measles H and F protein. After transduction of 
unstimulated CD34+ cells, CD133-LV outperformed VSVG-LV in repopulation 
experiments in first and second transplantation of gene marked CD34+ cells in NSG 
mice (Brendel et al., 2015). Recently, Girard-Gagnepain et al. showed up to 30% of 
GFP+ cells following gene transfer into unstimulated CD34+ cells with BaEVgp-LVs 
(Girard-Gagnepain et al., 2014). These LVs were pseudotyped with a chimeric 
glycoprotein consisting of the cytoplasmic tail of MLV-A and the glycoprotein of the 
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baboon endogenous retrovirus (BaEV). BaEV recognizes the receptors neutral amino 
acid transporter 1 (ASCT-1) and ASCT-2 (Rasko et al., 1999; Marin et al., 2000) that 
are present on CD34+ cells. In contrast to these observations, transduction 
efficiencies of unstimulated CD34+ cells did not exceed 10% using CD133-LV 
(Brendel et al., 2015). However, a 10-fold higher vector dose (MOI 10) was used for 
BaEVgp-LV mediated gene delivery. In addition, these high transduction efficiencies 
were only achieved in the presence of the transduction enhancer retronectin (Girard-
Gagnepain et al., 2014), whereas transduction of CD34+ cells by CD133-LV was 
performed in uncoated cell culture plates (Brendel et al., 2015).  
While the transduction of CD34+ cells with the LVs discussed above in the absence 
of a transduction enhancer results in relatively low transduction efficiencies, all of the 
vectors show stable transduction into long-term repopulating cells. Gene transfer into 
few of these cells, can reconstitute the entire hematopoietic system with cells 
carrying the corrected gene compensating for initially low transduction events. Others 
showed that CD133 is expressed on these primitive HSCs (Gallacher et al., 2000), 
and it could be confirmed for CD105 in this thesis. In contrast, the HSPC 
subpopulation transduced by BaEVgp-LV or RDTR/SCFHA-LV has not been fully 
characterized. Depending on the application, it might be favorable to transduce 
defined subpopulations by receptor-targeted LVs or to deliver a transgene into a 
broader HSPC population expressing the receptors of RDTR/SCFHA-LV or BaEVgp-
LV. To date, only CD105-LV and CD133-LV have been compared with the state of 
the art vector (VSVG-LV) side by side within the same animal. Thereby, the variability 
in repopulation experiments, influenced by the culture conditions, donor cells and 
individual mouse variability to engraft human cells, can be circumvented. Thus, final 
conclusions about the performance of all the HSC-targeted vectors discussed above 
should ideally be based on competitive repopulation experiments in vivo.  
 
4.4 Potential of receptor-targeted lentiviral vectors 
VSVG-LVs have been successfully used in clinical trials for the transduction of HSCs 
providing benefit to the patients (Cartier et al., 2009; Aiuti et al., 2013; Biffi et al., 
2013). The broad tropism of VSVG-LVs enables gene transfer into all mammalian 
cells including HSPCs, although this requires pre-stimulation of quiescent CD34+ 
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cells. In this thesis, selective and efficient gene transfer of the marker gene egfp into 
unstimulated long-term repopulating cells using CD105-LV was demonstrated. The 
therapeutic applicability of receptor-targeted LVs was shown by Brendel et al. using 
CD133-LV. Transduction of CD34+ cells from a X-CGD patient with CD133-LV 
transferring pg91phox resulted in the expression of the therapeutic gene in human 
cells for at least 10 weeks after transplantation of the modified cells into NSG mice 
(Brendel et al., 2015), which demonstrates the potential of receptor-targeted LVs for 
the use in clinical applications. However, for broad application the production of 
receptor-targeted LVs, such as CD105-LV, needs to be optimized. Currently, the 
yield of CD105-LV is 35-fold lower than that of VSVG-LV (Anliker et al., 2010). 
Nevertheless, a lower vector dose of CD105-LV is required for efficient transduction 
of long-term repopulating HSCs. Due to the selective transduction of CD105+ cells by 
CD105-LV, the cell population that is genetically modified is smaller compared to 
VSVG-LV transduced cells that include also CD105- cells. In combination with the 
lower amount of CD105-LV that is required for transduction, it is conceivable that the 
risk of multicopy vector integration and insertional mutagenesis is reduced compared 
to VSVG-LVs mediated gene therapy. However, the vector copy number within 
CD105-LV transduced cells needs to be analyzed. 
By the use of receptor-targeted LVs even in vivo gene transfer into HSCs is 
conceivable. The current standard for HSC-based gene therapy is ex vivo 
modification of CD34+ cells using VSVG-LVs (Cartier et al., 2009; Aiuti et al., 2013; 
Biffi et al., 2013). Ultimately, in vivo gene delivery into HSCs is desirable. Thereby, 
the procedure of harvesting cells from the patients could be prevented. Additionally, 
primitive CD34- cell populations, such as CD133+CD34- (Gallacher et al., 2000) that 
are currently lost during the purification of CD34+ cells from mobilized peripheral 
blood or BM could be transduced. However, LV-based in vivo gene transfer into 
HSCs faces several challenges. VSVG-pseudotyped LVs are not suitable for in vivo 
application, since systemical gene transfer is difficult to control due to the broad 
tropism. Furthermore, antibody and complement mediated immune response against 
the glycoprotein could be induced and cytotoxicity was observed when VSVG-LV was 
administered at high doses in vivo (DePolo et al., 2000; Higashikawa and Chang, 
2001; Watson et al., 2002). Moreover, VSVG-LVs poorly transduce unstimulated 
HSCs (Amirache et al., 2014). Clearly, LVs for in vivo HSC gene therapy should 
restrict gene transfer into specific target cells and result in efficient gene transfer into 
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unstimulated HSCs. Furthermore, safety issues concerning insertional mutagenesis, 
ectopic transgene expression, cytotoxic effects of the transgene or induction of an 
immune response must be clarified.  
By the use of receptor-targeted LVs, gene delivery is restricted to specific cells 
limiting vector integration and transgene expression to target cells. The high 
specificity of receptor-targeted LVs has been demonstrated in in vivo applications 
(Münch et al., 2011; Zhou et al., 2012; Abel et al., 2013). CD105 is not only 
expressed on HSCs, but also on activated endothelial cells, activated macrophages,  
mesenchymal stem cells and progenitor endothelial cells (Nassiri et al., 2011; Lin et 
al., 2013). This is important to keep in mind when planning in vivo studies. In vivo 
selectivity for HSCs could be achieved by local injection into the BM and possible 
further vector modifications such as cell specific promoters or the integration of 
microRNA (miRNA) target sequences into the 3’UTR of the transgene. Binding of 
complementary endogenous miRNA to the transcribed transgene reduces or 
eliminates the transgene translation, thereby detargeting the transgene expression 
within specific cell types (Heckl et al., 2011; Chiriaco et al., 2014). Other approaches 
include the use of integrase-deficient LVs (IDLVs) in combination with a tool allowing 
site-targeted integration into the host genome such as zinc-finger nucleases (ZFN) 
(Lombardo et al., 2007; Genovese et al., 2014; Hoban et al., 2015).  
Combining the safety mechanisms mentioned above, will enhance the safety of LVs 
further and will allow gene therapy of HSCs in vivo sometime in the near future. 
However, the risk associated with in vivo HSC gene therapy must be considered in 
relation to the severity of the disease.  
Receptor-targeted LVs are not only useful tools for gene therapy, but also for tracking 
and identification of cells, as demonstrated in this thesis. Cells expressing a specific 
surface protein can be selectively transduced by receptor-targeted LVs transferring 
reporter genes. Then, all cells derived from the target-receptor positive cell can be 
identified by the transferred reporter gene and analyzed in detail at various time 
points, e.g. regarding specific surface markers by flow cytometry and be assigned to 
specific cell populations. Thereby, the gene-marked cells can be traced, even if the 
targeted surface protein is not expressed during or after the differentiation process. 
The flexibility of the targeting system has been demonstrated by replacing the 
targeting ligand (Anliker et al., 2010). Thus, the approach shown in this thesis can be 
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easily transferred to other specific surface markers and will allow the identification of 
other potential markers on stem or progenitor cell populations.   
 
 
Figure 30: Tracking of gene-marked cells using receptor-targeted LVs. HSCs differentiate into 
multipotent and oligopotent progenitor cells and then into mature cells of the hematopoietic system. 
The various subpopulations are defined by the expression of specific surface proteins. Receptor 
targeted LVs can be used to gene mark cells of a specific subpopulation. By expression of the marker 
gene, the cells can be tracked during the differentiation process. LV with green surface proteins 
represents LV binding to receptor A (green), LV with pink surface proteins binds to receptor B (pink). 
Green bar represents reporter gene A, yellow bar reporter gene B. HSC, hematopoietic stem cell; 
MPP, multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; 
MEP, megakaryocyte/erythrocyte progenitor; GMP, granulocyte/macrophage progenitor; EP, 
erythrocyte progenitor; MkP, megakaryocyte progenitor; GP, granulocyte progenitor; MacP, 
macrophage progenitor; Pro-DC, dendritic cell progenitor; Pro-B, B-cell progenitor; Pro-T, T-cell 
progenitor and Pro-NK, natural killer cell progenitor.  
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6. ABBREVIATIONS 
α anti 
°C degree Celsius 
AAV adeno-associated virus 
ADA adenosine deaminase 
ALD adrenoleukodystrophy 
ATCC American Type Culture Collection 
BFP blue fluorescent protein 
BM  bone marrow 
bp base pair 
cap capsid protein 
CD cluster of differentiation 
CD cluster of differentiation 
cDNA complementary DNA 
CGD chronic granulomatous disease 
CMV cytomegalovirus 
DARPin designed ankyrin repeat protein 
DEPC diethyl dicarbonate 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
Env envelope protein 
EpCAM epithelial cell adhesion molecule 
et al. and others 
F fusion protein 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
for forward 
fw forward 
g gram 
GFP green fluorescent protein 
GM-CSF granulocyte colony stimulating factor 
GOI genomes per cell 
H hemagglutinin 
HEK human embryonic kidney 
Her2/neu human epidermal growth factor receptor 2 
HIV human immunodeficiency virus 
HPLC high-performance liquid chromatography 
HRP horseradish peroxidase 
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HSC hematopoietic stem cell 
HSCT hematopoietic stem cell transplantation 
HSPG heparan sulfate proteoglycan 
HSV-TK herpes simplex virus thymidine kinase 
IL2R Interleukin-2 receptor 
ITR inverted terminal repeat 
K potassium 
kDa kilo Dalton 
kg kilogram 
l liter 
LB Luria-Bertani 
LDL-R low-density lipid receptor 
LMO2 LIM domain only 2 
LTR long terminal repeat 
luc luciferase 
LV lentiviral vector 
m mili 
Mg Magnesium 
MLD metachromatic leukodystrophy 
MLV murine leukemia virus 
MOI multiplicity of infection 
mRNA messenger RNA 
MV measles virus 
ns not significant 
NSG mice NOD-scid IL2R-/- mice 
ORF open reading frame 
p.t. post transduction 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PBS M/K PBS supplemented with Mg/K 
PCR polymerase chain reaction 
PEI polyethylenimine 
PID Primary immune deficiencies 
qPCR quantitative real-time PCR 
rep viral regulatory proteins 
rev reverse 
RNA ribonucleic acid 
rpm rounds per minute 
RT reverse transcription 
rv reverse 
scAAV AAV vector with self-complementary genome 
SCF stem cell factor 
scFv single chain Fragment variable 
SFFV spleen focus forming virus 
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SIN-LV self-inactivating LV 
ssAAV single-stranded AAV 
T-ALL T-cell lymphoblastic leukemia 
TPO thrombopoietin 
tu transducing unit 
U unit 
V volt 
VP viral protein 
VSV vesicular stomatitis virus 
VSVG envelope glycoprotein of VSV 
WAS Wiskott-Aldrich syndrome 
∆ delta 

 
micro 
gamma 
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